Document:

EXHIBIT 10.1

--------------------------------------------------------------------------------
[**] = This mark indicates portions of the text which have been omitted and
filed separately with the Securities and Exchange Commission pursuant to a
request for confidential treatment of such omitted text in accordance with Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

                     AMENDED AND RESTATED LICENSE AGREEMENT

                         Effective as of March 24, 2006

                                      Among

                 THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

                                AUBURN UNIVERSITY

                                 DUKE UNIVERSITY

               GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.

                                       and

                          IMMTECH PHARMACEUTICALS, INC.

--------------------------------------------------------------------------------
<PAGE>

                     AMENDED AND RESTATED LICENSE AGREEMENT

      THIS AMENDED AND RESTATED LICENSE AGREEMENT is made effective as of March
24, 2006 (the "Effective Date"), among THE UNIVERSITY OF NORTH CAROLINA AT
CHAPEL HILL (hereinafter referred to as "UNC"), AUBURN UNIVERSITY, DUKE
UNIVERSITY, GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (hereinafter all
of the foregoing entities, including UNC, shall be collectively referred to as
the "Licensors"), and IMMTECH PHARMACEUTICALS, INC., a corporation organized and
existing under the laws of the State of Delaware (hereinafter referred to as
"Licensee").

                               W I T N E S S E T H

      WHEREAS, as anticipated by that certain Formation of Research
Collaboration Letter Agreement effective January 15, 1997, as amended by (a)
that certain Amendment to Letter Agreement effective as of October 15, 1997, (b)
that certain Second Amendment to Letter Agreement effective as of January 15,
1998, and executed in May, 1998 (the "Second Amendment"), (c) that certain Third
Amendment to Letter Agreement effective as of October 1, 1998, and executed in
January, 1999 (the "Third Amendment"), (d) that certain Fourth Amendment to
Letter Agreement effective as of October 1, 1998, and executed in March, 1999,
(e) that certain Addendum to Fourth Amendment to Letter Agreement executed in
April, 1999, and (f) that certain Second Addendum to Fourth Amendment to Letter
Agreement executed in April, 1999 (collectively with all such amendments and
addenda, the "1997 Letter Agreement"), between UNC on behalf of the Licensors,
Licensee and Pharm-Eco Laboratories, Inc. ("Pharm-Eco"), Licensee completed its
initial public offering (the "IPO"), which became effective on or about April
28, 1999.

      WHEREAS, it was anticipated in the 1997 Letter Agreement that upon
completion of its IPO, Licensee and the Licensors would enter into an agreement
with respect to the licensing of the Future Compounds (as defined below).

      WHEREAS, such license agreement was entered into by and among the parties
hereto as of January 28, 2002 (the "Original License Agreement").

      WHEREAS,  the parties  hereto  wish to amend and  restate  the  Original
License Agreement as provided herein;

      WHEREAS, the parties hereto acknowledge that the goals, principles and
objectives of the Foundation Program (as defined below) are both scientific and
charitable as follows: (i) to accomplish the scientific and programmatic goals
as set forth in the grant proposals submitted by UNC to the [**] under which
significant funding has been provided for the development of the Foundation
Product; and (ii) to ensure that innovations and rights related to the
Foundation Product are managed and commercialized, and public health solutions
are optimized, in a manner

-------------
** Confidential Treatment Requested.

<PAGE>

that enables subsequent accessibility (with respect to cost, quantity and
applicability) of the Foundation Product to the people most in need in the
developing countries of the world (collectively the "Grant Objectives").

      NOW, THEREFORE, for and in consideration of the covenants, conditions, and
undertakings hereinafter set forth, it is agreed by and between the parties as
follows:

1.    Definitions

      1.1 "Affiliate" means, with respect to any particular Person, any other
Person which controls, is controlled by, or is under common control with such
particular Person. A Person shall be regarded as in control of another Person if
the first Person owns or controls, directly or indirectly, at least fifty
percent (50%) of the voting stock (or other voting equity) of the second Person.
In the case of a Non-Profit Entity, control will be deemed to exist if any
Person possesses, directly or indirectly, the power to direct or cause the
direction of the management and policies of such Non-Profit Entity.

      1.2 "Clinical Research Subcontract" means that certain subcontract by and
between Licensee and UNC dated March 29, 2001, as amended from time to time.

      1.3 "Current Compounds" means all technology and compounds owned by one or
more of the Licensors and either licensed or optioned to Pharm-Eco as of the
date of the 1997 Letter Agreement or set forth on Exhibit A to the 1997 Letter
Agreement.

      1.4 "Developing Country" means any country (i) which has a Per Capita GDP
less than the Per Capita GDP Threshold and (ii) for which the World Health
Organization (the "WHO") has determined the presence of Human African
Trypanosomiasis.

      1.5 "Force Majeure" means prevention or delay in the performance of a
party's obligations under this Agreement if such prevention or delay is by any
cause beyond such party's control, including, but not limited to, acts of God,
fire, explosion, disease, weather, war, insurrection, civil strife, riots,
government action, or power failure. Performance shall be excused only to the
extent of and during the reasonable continuance of such disability.

      1.6 "Foundation" means the non-profit foundation or any successor
non-profit foundation funding the Foundation Program.

      1.7 "Foundation Product" means the Licensed Product derived from the
compound DB289 for the treatment of Trypanosomiasis within Developing Countries
and which are developed under the Foundation Program.

      1.8 "Foundation Program" means research and development programs funded by
grants from the Foundation received by UNC under terms of the Grant Agreements.

      1.9 "Future Compounds" means all technology and compounds developed or
invented by one or more of the Licensors which either (a) was developed or
invented subsequent to January 15, 1997, (i) through use of Licensee-sponsored
research funding, (ii) through use of

                                      -2-
<PAGE>

Governmental Funding made available to any of the Licensors, (iii) through use
of funds expended by Licensee or obtained through Licensee's efforts or
assistance, including, without limitation, all of the funds provided (and to be
provided) in connection with the Foundation Program or by any other organization
which Licensee introduces to any of the Licensors and which funds a research
program, (iv) through the Foundation Program, (v) for which Licensee funded any
third party research or testing previously approved by any of the Licensors,
(vi) for which Licensee has funded, or agreed or committed to fund, any patent
applications or the maintenance of any patents or patent applications, or (vii)
by Dr. Richard Tidwell's or Dr. David Boykin's laboratories at UNC and Georgia
State University, respectively, and are dications or related molecules and were
not or are not developed through the use of any funding from any governmental
agency or authority, other than Governmental Funding, and for which the
Licensors have the right to include in this Agreement, or (b) was developed or
invented on or prior to January 15, 1997, through use of National Cooperative
Drug Development Grants or funding and which were not, as of such date, licensed
to Pharm-Eco pursuant to that certain License Agreement dated August 25, 1993,
between UNC and Pharm-Eco, or which are otherwise not Current Compounds.

      1.10 "Global Access Plan" means the Global Access Plan, attached to the
Clinical Research Subcontract as Exhibit C, associated with the Foundation
Product being developed pursuant to the Foundation Program, which the parties
hereto agree serves as the strategy to be used by them to achieve the Grant
Objectives.

      1.11 "Governmental Funding" means (a) that certain National Cooperative
Drug Development Grant awarded to the Licensors and Pharm-Eco during the period
from 1993 to 1997, and (b) any Small Business Innovation Research grant or Small
Business Technology Transfer ("STTR") grant which was or is applied for jointly
by Licensee and any one or more of the Licensors.

      1.12 "Grant Agreements" means the agreements entered into by and between
UNC and the Foundation as a result of the Foundation grant awarded to UNC, dated
November 8, 2000 and ________, 2006 (as the same may from time to time be
supplemented and amended by UNC and the Foundation).

      1.13 "Grant Objectives" has the meaning set forth in the Recitals hereto.

      1.14 "License" has the meaning set forth in Section 2.2 hereto.

      1.15 "Licensed Field" means, and is limited to, the practice of the Future
Compounds (and the Current Compounds, if covered under this Agreement pursuant
to Section 26.1) for all fields of use.

      1.16 "Licensed Products" means any method, procedure, product, or
component part thereof whose manufacture, use or sale includes any use of
University Technology or is covered by one or more valid and unexpired claims of
the Patent Rights.

      1.17 "Licensed Territory" means the entire world.

                                      -3-
<PAGE>

      1.18 "Net Sales" means the total Net Sales Price of Licensed Products sold
by Licensee and its Affiliates, after deducting actual allowances for returned
or defective goods, less discounts. Licensed Products will be considered sold
when billed out, when delivered, or when paid for before delivery, whichever
first occurs. Net Sales shall not include sales for pre-clinical or clinical
trial purposes.

      1.19 "Net Sales Price" means the actual sales receipts, less any charges
for (a) sales taxes, tariffs, duties or other taxes separately stated on the
invoice, and (b) shipping and insurance charges.

      1.20 "Non-Profit Entity" means any non-profit or charitable entity, agency
or organization that is not an Affiliate of Licensee.

      1.21 "Patent Rights" means the rights of any Licensor in (a) any U.S.
patents and/or patent applications which cover, or relate to, the Future
Compounds, and/or their use or manufacture, and which are owned, exclusively
licensed, or otherwise controlled by the Licensors, and which patents and/or
patent applications were filed prior to or are filed during the term of this
Agreement, (i) for which such Licensor has the right to grant a license
hereunder, and (ii) for which the inventions claimed therein were made in the
performance of research funded through the use of (A) Licensee-sponsored
research funding under a sponsored research agreement, (B) Governmental Funding
made available to any of the Licensors, or (C) funds expended by Licensee or
obtained through Licensee's efforts or assistance, including, without
limitation, all of the funds provided (and to be provided) in connection with
the Foundation Program or by any other charitable or non-profit organization
which funds a program in which both Licensee and any Licensor are participants,
and (b) any continuations, continuations in part, divisionals, provisionals,
continued prosecution applications, or reissues thereof, any PCT application
corresponding to any of the foregoing, and any patents and patent applications
(or their functional equivalents) in foreign countries corresponding to any of
the foregoing, in each case subject to the statutory rights of the United States
Government in inventions which were made in the performance of research which it
funded. As of the Effective Date, the patents and patent applications included
in the Patent Rights are set forth in Exhibit A attached hereto.

      1.22 "Per Capita GDP" means, for any particular country, the per capita
gross domestic product of such country, as determined by the Statistics Division
of the United Nations Secretariat and International Labour Office (or any
successor thereto), for the most recent year for which such data is then
available.

      1.23 "Per Capita GDP Threshold" means, for any particular country, the
amount of $10,000; provided, however, that, for each year after 1998 for which
both the per capita gross domestic product for such country and the annual
inflation rate for such country (in each case as determined by the Statistics
Division of the United Nations Secretariat and International Labour Office (or
any successor thereto)) is then available, such threshold amount shall be
increased by the annual inflation rate for such country for each such year after
1998, such that such threshold amount is compounded on an annual basis by the
annual inflation rate for such country.

      1.24 "Person" means any natural person or any corporation, company,
partnership, limited liability company, trust, estate, association,
unincorporated association, governmental

                                      -4-
<PAGE>

authority, custodian, nominee, or any other individual entity or organization in
its own or any representative capacity, or other entity.

      1.25 "University Technology" means any published or unpublished research
and development information, know-how and technical data (but excluding any
Patent Rights) which is in the possession of any of the Licensors or their
respective employees on or after the Effective Date, or which is developed by
any Licensor during the term of this Agreement, (a) for which any Licensor has
the right to grant a license hereunder, (b) which is necessary for the practice,
use or further development of the Future Compounds, and (c) which resulted,
results, was developed, or is developed through the use of (i)
Licensee-sponsored research funding under a sponsored research agreement, (ii)
Governmental Funding made available to any of the Licensors, or (iii) funds
expended by Licensee or obtained through Licensee's efforts or assistance,
including, without limitation, all of the funds provided (and to be provided) in
connection with the Foundation Program or by any other charitable or non-profit
organization which funds a program in which both Licensee and any Licensor are
participants.

2.    Grant of Licenses and Term

      2.1 The Licensors hereby grant to Licensee and to Licensee's Affiliates,
to the extent of the Licensed Territory, a non-exclusive right and license to
use University Technology in the Licensed Field and the non-exclusive right to
make, use and sell Licensed Products incorporating (or manufactured using) such
University Technology in the Licensed Field, subject to all the terms and
conditions of this Agreement (the "Technology License"). Licensee may, subject
to the prior written approval of UNC on behalf of the Licensors, which approval
shall not be unreasonably withheld or delayed, grant sublicenses of the
Technology License and its rights under this Section 2.1. Sublicensees of
Licensee may not, unless permitted by the terms of the sublicense agreement,
further sublicense the rights granted to it in such sublicense agreement without
the approval of UNC (on behalf of the Licensors), which approval may not be
unreasonably withheld or delayed.

      2.2 The Licensors hereby grant to Licensee and to Licensee's Affiliates,
to the extent of the Licensed Territory so long as valid and unexpired Patent
Rights exist in any Licensed Territory, the exclusive license under and to the
Patent Rights and the exclusive right to make, use and sell Licensed Products
incorporating (or manufactured using) such Patent Rights (and not including any
University Technology) in the Licensed Field, upon the terms and conditions set
forth in this Agreement (the "Patent License", and collectively with the
Technology License, the "Licenses"). Licensee may, subject to the prior written
approval of UNC on behalf of the Licensors, which approval shall not be
unreasonably withheld or delayed, grant sublicenses of the Patent License and
its rights under this Section 2.2. Sublicensees of Licensee may not, unless
permitted by the terms of the sublicense agreement, further sublicense the
rights granted to it in such sublicense agreement without the approval of UNC
(on behalf of the Licensors), which approval may not be unreasonably withheld or
delayed.

      2.3 Each of the Licenses granted herein is for a term beginning on the
Effective Date and, unless terminated sooner as provided in this Agreement,
ending upon the expiration of the last to expire patent included in the Patent
Rights.

                                      -5-
<PAGE>

      2.4 Licensee shall not disclose any item of unpublished University
Technology furnished by the Licensors to Licensee pursuant to Section 2.1 above
to third parties during the five (5) year period commencing on the date that
such item of unpublished University Technology is first furnished to Licensee,
provided, however, that disclosure may be made of any such item of University
Technology at any time: (a) with the prior written consent of UNC (on behalf of
the Licensors), which shall not be unreasonably withheld or delayed, or (b)
after such item shall have become public through no fault of Licensee, or (c) if
such item was known by Licensee at the time of the disclosure, as shown by
documents in existence at such time, or (d) to the Securities and Exchange
Commission, the NASD, NASDAQ, the Food and Drug Administration, and any other
U.S. or foreign governmental or regulatory agency or authority to which such
disclosure is necessary or advisable, in which case, if such disclosure is
advisable but not necessary, then Licensee shall (1) obtain the consent of UNC
on behalf of the Licensors, which consent shall not be unreasonably withheld or
delayed, and (2) to the extent practicable, request confidential treatment of
such disclosed University Technology by the receiving agency or authority, or
(e) to any sublicensees who have agreed to terms no less restrictive than those
in this Section, or (f) if required by law, a court of competent jurisdiction,
or any governmental or regulatory agency or authority.

      2.5 The Licensors each represent and warrant to Licensee, as of the date
they execute and deliver this Agreement, that (a) they have the authority,
right, and power to grant to Licensee the Licenses (and the rights thereunder)
under this Agreement, (b) to the best of their knowledge, after reasonable
inquiry, there are no agreements, statutes, rules or regulations prohibiting,
restricting, or modifying such grant or limiting the Patent Rights or University
Technology covered by such Licenses, and (c) to the best of their knowledge,
after reasonable inquiry, they have not granted, sold or otherwise transferred
to any Person any licenses or other rights to any of the Patent Rights or
University Technology or Future Compounds which might reasonably be expected to
conflict with or limit the rights and Licenses granted to Licensee under this
Agreement. Notwithstanding the foregoing, any and all Licenses granted hereunder
are subject to the statutory rights of the United States Government which arise
out of its sponsorship of the research which led to the discovery or development
of Future Compounds licensed herein. Notwithstanding anything else contained in
this Agreement, each of the Licensors shall, during the term of this Agreement,
use its best efforts not to sell, grant, license, sublicense, or otherwise
transfer to any third party any rights to any Future Compounds or Patent Rights
(or to any University Technology on an exclusive basis) (or to anything that
would be a Future Compound, Patent Right or item of University Technology but
for such sale, grant, license, sublicense, or other transfer) and the other
provisions of this Agreement. If any Licensor becomes aware that it has entered
into any transaction described in the preceding sentence, then it shall promptly
notify Licensee of such transaction and state the other party to and the
principal terms of such transaction, and it shall take all reasonable efforts to
negotiate an agreement with such third party to reduce as much as practicable
the impairment, limitation or conflict with the rights granted to Licensee (or
which would have been granted to Licensee but for such transaction) under this
Agreement which such transaction has created. Licensee shall, shortly after the
execution and delivery of this Agreement, prepare a "plain English" summary of
each Licensor's obligations under this Agreement and provide each Licensor with
a copy of such summary. Each Licensor shall, within fifteen (15) days of its
receipt of such summary, distribute such summary to its scientists, professors,
appropriate students, employees, and other relevant persons, in an effort to
prevent any actions by any of such persons which might impair any of Licensee's
rights under

                                      -6-
<PAGE>

this Agreement, as well as a copy to Licensee. The final decision regarding the
content of each summary shall be decided solely by the Licensor receiving the
summary.

      2.6 Any sublicenses granted pursuant to this Article 2 shall be in
accordance with the terms and conditions of this Agreement. Licensee shall
provide UNC (on behalf of the Licensors) with a copy of all sublicense
agreements within thirty (30) days of the full execution and delivery by the
sublicensee of such sublicense agreement to Licensee. Licensee shall use
commercially reasonable efforts (which efforts may include bringing suit against
a sublicensee if economically justifiable) to enforce its rights under each
sublicense agreement. Upon the termination or expiration of this Agreement,
Licensee shall assign to the Licensors each sublicense agreement, as
contemplated by Section 5.4.

      2.7 UNC shall provide to Licensee, as of June 30 and December 31 of each
year, within thirty (30) days of such dates, a revised Exhibit A to this
Agreement which shall have added to it all new Patent Rights to any Future
Compounds which were developed or obtained during each such six (6) month
period. If Licensee believes that any information on such revised Exhibit A is
incorrect, then Licensee and UNC (on behalf of the Licensors) shall cooperate in
good faith to address such belief to the reasonable satisfaction of the parties.
Each revised Exhibit A shall be accompanied by a statement of an authorized
signatory of each Licensor who has obtained any of such new Patent Rights that,
to the best of their knowledge, after reasonable inquiry, they have not granted,
sold or otherwise transferred to any Person any licenses or other rights to any
of the new Patent Rights, or to any University Technology related thereto, which
might reasonably be expected to conflict with or limit the rights and Licenses
granted to Licensee (or which would have been granted to Licensee but for such
grant, sale, or other transfer) under this Agreement.

      2.8 The Licenses granted to Licensee in this Agreement shall not be
construed to confer any rights upon Licensee by implication, estoppel, or
otherwise as to any technology or intellectual property owned solely or jointly
by one or more Licensors which are not included in or part of the Patent Rights
or University Technology.

      2.9 The Licensee acknowledges that the Licenses with respect to the
Foundation Product(s) granted to Licensee in this Agreement are made partly in
reliance upon Licensee's exercising the rights pertaining to such Licenses in a
manner that is consistent with and in furtherance of the Grant Objectives and
the Global Access Plan.

3.    License Fee and Royalties

      3.1 Licensee will pay to UNC on behalf of the Licensors a license fee in
the form of reimbursement of the costs (including attorney's fees) arising out
of the patenting of the Future Compounds pursuant to and in accordance with
Article 9 of this Agreement. The reimbursement of patenting costs shall be
non-refundable and shall not be a credit against any other amounts due
hereunder. Reimbursement of patenting costs shall be due upon monthly billings
from UNC containing invoices of such patenting costs with reasonable supporting
documentation.

      3.2 (a) (i) Subject to clauses (ii) through (iv) of this Section 3.2(a),
beginning on the Effective Date and continuing for the term of this Agreement,
Licensee will pay the

                                      -7-
<PAGE>

Licensors, collectively as a group, and payable through UNC, an aggregate
running royalty (the "Royalty") of [ ** ] of the aggregate worldwide Net Sales
of any and all Licensed Products for each fiscal year of Licensee and its
Affiliates.

            (ii) Subject to clauses (iii) and (iv) of this Section 3.2(a) and
      subject to Section 3.2(b), beginning on the Effective Date and continuing
      for the term of this Agreement, Licensee will pay the Licensors,
      collectively as a group, and payable through UNC, a Royalty of [ ** ] of
      the aggregate worldwide Net Sales of any and all Licensed Products to
      Non-Profit Entities for each fiscal year of Licensee and its Affiliates.

            (iii) [ ** ] on Net Sales of Foundation Products.

            (iv) Notwithstanding anything else contained in this Agreement,
      [ ** ] under either Section 3.2(a) or Section 3.2(b) (and [ ** ] shall be
      payable under Section 3.6 in the case of sublicense arrangements) for
      sales of any Licensed Product or of any Future Duke Licensed Product, as
      defined below, if [ ** ] on (A) the structure (or "composition of matter")
      of the active ingredient, (B) the manufacturing process for the active
      ingredient, or (C) the use for which such active ingredient is being used.
      For any particular country, if [ ** ] (covering the structure (or
      "composition of matter"), the manufacture, or the use for which it is
      being used) for the active ingredient of any Licensed Product or of any
      Future Duke Licensed Product exists in such country, or if [ ** ] in such
      particular country, then [ ** ] shall be payable under either Section
      3.2(a) or Section 3.2(b) (and [ ** ] shall be payable under Section 3.6 in
      the case of sublicense arrangements) for sales in or to such country of
      any Licensed Product or of any Future Duke Licensed Product incorporating,
      using or based on such active ingredient.

            (b) With respect to any Future Compounds invented by Duke University
subsequent to the date of this Agreement (the "Future Duke Licensed Products"),
and solely to the extent required by applicable federal laws and regulations,
Licensee and UNC (or Duke University), understanding that certain tax
ramifications exist in regard to royalty rates, agree to negotiate in good faith
all Royalty rates for sales (such rates to be negotiated for both sales to
Non-Profit Entities and for sales to other customers) of all Future Duke
Licensed Products on an annual basis (as of the end of Licensee's fiscal year)
for all of the Future Duke Licensed Products which are to be based on Future
Compounds invented by Duke University which have become, during such twelve (12)
month period, subject to the Licenses granted to Licensee under this Agreement
for Future Compounds, but, in any event, such Royalty rates will be fairly
representative of royalty rates in the same industry for comparable technology
negotiated at arms' length. Licensee understands and acknowledges that, if such
Royalty is negotiated by UNC, then any such Royalty rate shall be subject to
Duke University's approval, which shall not be unreasonably withheld or delayed.
In the event that Licensee and UNC (or Duke University) fail to reach mutually
acceptable terms within ninety (90) days after commencement of negotiations with
respect to the Royalty rates to be paid to UNC on behalf of Duke University for
any such Future Duke Licensed Product (the "Negotiation Period"), then, unless
Duke University submits the matter to arbitration in accordance with Section
28.1 of this Agreement,

-------------
** Confidential Treatment Requested.

                                      -8-
<PAGE>

the Royalty for such Future Duke Licensed Products shall be the same as the
Royalty on Licensed Products which are not Future Duke Licensed Products.

            (c) If a third party markets or sells any product in a market in
which Licensee or any of Licensee's Affiliates markets or sells a Licensed
Product, and (i) such third party product is generically equivalent to such
Licensed Product, or (ii) such third party product has a chemical structure that
is covered by any Patent Right that Licensee has under this Agreement on any of
the Future Compounds incorporated or used in such Licensed Product, or on which
such Licensed Product is based, then the Royalty for such Licensed Product shall
be reduced by [ ** ] in such market for as long as such third party markets or
sells such third party product in such market; provided, however, that in any
event under clause (ii) above, Licensee shall take or have taken action under
Section 9.4 hereof for the purpose of stopping the marketing or sale of such
third party product.

            (d) Notwithstanding anything else to the contrary contained in this
Agreement, [ ** ] shall be payable on sales of any Licensed Product for [ ** ]
purposes. In addition, no Royalties shall be payable on any transfer of Licensed
Products between any of Licensee, its sublicensees, and any sublicensee or
Affiliate of any of them. Only one Royalty shall be paid for the sale of any
Licensed Product.

            (e) Licensee shall use, and shall instruct its Affiliates to use,
commercially reasonable efforts to collect the payments that Licensee or its
Affiliates are owed for sales of Licensed Products.

      3.3 (a) Licensee shall make semi-annual written reports to UNC during the
life of this Agreement (the "Summary Reports"), with each Summary Report
covering one-half of Licensee's fiscal year and stating the number, description,
and aggregate Net Sales of Licensed Products sold or otherwise disposed of
during the reporting period and upon which any Royalty is payable as provided in
Section 3.2 hereof, and the amount of any such Royalty which is due. The first
Summary Report shall include all such Licensed Products, if any, so sold or
otherwise disposed of prior to the date of such report. The Summary Report for
the first half of Licensee's fiscal year shall be due [ ** ] after the end of
the first half, and shall contain an estimate of the information required to be
set forth therein. The Summary Report for the second half of Licensee's fiscal
year shall be due [ ** ] after the end of Licensee's fiscal year, and shall
contain actual amounts for both the first half and the second half of such
fiscal year. Each Summary Report may include any adjustments that may be
necessary for any prior reporting period, including, for example, adjustments
for returns or defective goods.

            (b) Until Licensee has achieved a first commercial sale of a
Licensed Product, a report shall be submitted by Licensee to UNC by the due
dates set forth in Section 3.3(a) above (a "Status Report") which will include a
full written report describing Licensee's technical and other efforts made
towards such first commercial sale for all Licensed Products then under
development.

** Confidential Treatment Requested.

                                      -9-
<PAGE>

      3.4 Concurrently with the making of each Summary Report provided for in
Section 3.3(a), Licensee shall pay to UNC the Royalties specified in Section 3.2
of this Agreement which are due on the Licensed Products included in such
report.

      3.5 In the event of default in payment of any payment owing to the
Licensors under the terms of this Agreement, and if it becomes necessary for the
Licensors to undertake legal action to collect said payment, then Licensee shall
reimburse the Licensors for all reasonable legal fees and costs actually
incurred by the Licensors in connection therewith; provided, however, that if
any matter involving any payment due or alleged to be due is submitted to
arbitration in accordance with Section 28.1, then such legal fees and costs
shall be allocated as the arbitration tribunal shall determine.

      3.6 (a) If Licensee sublicenses its rights with respect to the Future
Compounds or the Licensed Products pursuant to Sections 2.1 and 2.2, then
Licensee will pay to UNC, for the benefit of the Licensors, in lieu of any
Royalty due under Section 3.2, (i) [ ** ] of all signing, milestone, and other
non-royalty payments received by Licensee from each such sublicensee pursuant to
its sublicense arrangement; provided, however, that if any of such payments are
made for the reimbursement or funding of documented costs (excluding indirect
costs and expenses) incurred by Licensee for research and clinical development
of Future Compounds, then Licensee will pay to UNC, for the benefit of the
Licensors, [ ** ] of all such signing, milestone, and other non-royalty payments
received by Licensee from each such sublicensee pursuant to its sublicense
arrangement, and (ii) [ ** ] of all royalty payments received by Licensee from
each such sublicensee pursuant to its respective sublicense arrangement.

            (b) With respect to Future Compounds invented by Duke University
subsequent to the Effective Date or Future Duke Licensed Products, and solely to
the extent required by applicable federal laws and regulations, Licensee and UNC
(on behalf of Duke University) will negotiate in good faith for the appropriate
percentages of signing, milestone, other non-royalty payments, and royalty
payments received by Licensee from each sublicensee of any Future Compounds
invented by Duke University subsequent to the Effective Date or any Future Duke
Licensed Products, consistent with the negotiation process described in Section
3.2 above and, if such negotiation process shall be unsuccessful during the time
period set forth therein, then, unless Duke University submits the matter to
arbitration in accordance with Section 28.1 of this Agreement, the percentages
shall be the same as set forth in Section 3.6(a) above.

      3.7 (a) To the extent that Licensee uses any other proprietary technology
other than that licensed to Licensee by this Agreement (except as provided below
in Section 3.7(b) for Future Duke Licensed Products) to manufacture or sell a
Licensed Product, the amount of the Royalty will be reduced to the extent
necessary so that the sum of the total Royalties paid by Licensee to UNC on
behalf of the Licensors plus the total royalties paid by Licensee to any third
parties with respect to such Licensed Product will not, in the aggregate, exceed
[ ** ] of the worldwide Net Sales of such Licensed Product, excluding sales to
Non-Profit Entities and sales of Foundation Products, provided, however, that in
no event will the amount of the Royalty owed

-------------
** Confidential Treatment Requested.

                                      -10-
<PAGE>

to the Licensors be less than [ ** ] of the worldwide Net Sales of such Licensed
Product, excluding sales to Non-Profit Entities and sales of Foundation
Products.

            (b) With respect to Future Duke Licensed Products, and solely to the
extent required by applicable federal laws and regulations, Licensee and UNC
will negotiate in good faith for an appropriate reduction in the Royalty due UNC
under Licensee's Licenses for each such Future Duke Licensed Product consistent
with the negotiation process described in Section 3.2 above and, if such
negotiation process shall be unsuccessful during the time period set forth
therein, then, unless Duke University submits the matter to arbitration in
accordance with Section 28.1 of this Agreement, the reduction in the Royalty for
such Future Duke Licensed Products shall be the same as the reduction in the
Royalty on Licensed Products which are not Future Duke Licensed Products.

      3.8 UNC shall be responsible for distributing to the other Licensors any
share to which they are entitled of payments made by Licensee to UNC under this
Agreement.

      3.9 If in any fiscal year of Licensee during the term of this Agreement
after Licensee has received approval from the appropriate regulatory authority
of a New Drug Application (or its equivalent elsewhere in the Licensed
Territory), the total amounts paid or payable to UNC (for the benefit of the
Licensors) under Sections 3.2 and 3.7 combined are less than [ ** ], then
Licensee shall pay to UNC (for the benefit of the Licensors) such amount that,
when combined with the amounts paid or payable by Licensee under Sections 3.2
and 3.7, shall total [ ** ].

      3.10 To the extent that any of the Licensors shall have received payments
during the first or second half of Licensee's fiscal year from Licensee pursuant
to a sponsored research agreement between Licensee and any such Licensor that
relates to any Licensed Product, the amount of Royalty payable to the Licensors
under this Article 3 shall be reduced by [ ** ] by all of the Licensors combined
pursuant to such sponsored research agreement during the relevant six (6) month
period, such reduction not to exceed [ ** ] of the Royalty otherwise payable in
that period. Any remaining funds received by the Licensors pursuant to such
sponsored research agreement which have not yet been credited against the
Royalty payable in such period shall be carried forward and applied to the
Royalty payable to the Licensors in each subsequent six (6) month period,
thereby reducing the Royalty actually payable by up to [ ** ] of the Royalty
otherwise payable for each such period, until the entire amount received by the
Licensors pursuant to the sponsored research agreement has been credited against
the Royalties payable under Sections 3.2 and 3.7.

4.    Commercialization Efforts

      4.1 Licensee shall use its commercially reasonable efforts to proceed
diligently with the manufacture and sale of Licensed Products and shall
earnestly and diligently work to obtain regulatory approval to sell Licensed
Products and to offer and continue to offer for sale such Licensed Products
after obtaining such approvals, both under reasonable conditions, during the
term of this Agreement.

-------------
** Confidential Treatment Requested.

                                      -11-
<PAGE>

      4.2 (a) Licensee shall use commercially reasonable efforts to meet a
schedule of performance milestones for each lead Future Compound. The completion
dates of each milestone with respect to any particular lead Future Compound
shall count from the date on which such lead Future Compound is selected for
clinical development by mutual agreement of Licensee and the Licensors, such
agreement not to be unreasonably delayed or withheld by any party. The schedule
of milestones for each lead Future Compound is as follows:

                              Milestone*                        Deadline
                                                        (Years After Selection
                                                            of Lead Compound)

            Completion of pre-clinical trials.                   [ ** ]
            Filing of IND.                                       [ ** ]
            Completion of Phase I clinical trials.               [ ** ]
            Completion of Phase II clinical trials.              [ ** ]
            Completion of Phase III clinical trials.             [ ** ]
            Filing of New Drug Application.                      [ ** ]

            * or their equivalents elsewhere in the Licensed Territory

            (b) The date of selection of the lead compound known as "DB-075"
shall be the Effective Date. With respect to the lead compound known as "DB-289"
the following milestones shall apply in lieu of the milestones set forth in
Section 4.2(a):

                              Milestone*                        Deadline

            Completion of Phase II clinical trials.              [ ** ]
            Completion of Phase III clinical trials.             [ ** ]
            Filing of New Drug Application.                      [ ** ]

            * or their equivalents elsewhere in the Licensed Territory

            (c) Failure to achieve any of the milestones for any lead compound
shall result in [ ** ] to such lead compound to [ ** ] to such lead compound,
such selection to be in the sole discretion of the Licensors, but not before the
(i) expiration of reasonable grace periods to be agreed upon by Licensee and the
Licensors, such agreement not to be unreasonably delayed or withheld by any
party hereto, and (ii) exhaustion of good faith efforts on the part of the
parties hereto to agree on the appropriate adjustment of such milestones, taking
into account the conditions and results experienced by Licensee in the
performance of its duties hereunder, such agreement not to be unreasonably
delayed or withheld by any party hereto.

            (d) The milestones set forth in this Section 4.2 represent
Licensee's realistic estimate of the schedule it will be able to keep in the
event that there are no unexpected technical

-------------
** Confidential Treatment Requested.

                                      -12-
<PAGE>

or clinical obstacles outside of Licensee's reasonable control and not due to
Licensor's financial constraints (other than financial constraints resulting
from delayed or canceled funding due from collaborators such as the Foundation).
Adverse results at any stage could significantly extend the periods required to
meet any or all of the milestones listed.

      4.3 If this Agreement becomes effective or terminates or expires during a
calendar year, then the Minimum Royalty payable to UNC under Section 3.9 for the
portion of such year during which this Agreement is in effect shall be
determined by multiplying the Minimum Royalty set forth in Section 3.9 for the
year in which this Agreement becomes effective, terminates or expires, by a
fraction, the numerator of which shall be the number of days during such
calendar year for which this Agreement is in effect and the denominator of which
shall be 365.

5.    Cancellation.

      5.1 It is expressly agreed that, notwithstanding the provisions of any
other Section of this Agreement, if Licensee should fail to deliver to UNC any
Royalty at the time or times that the same should be due to UNC on behalf of the
Licensors where there is not a dispute between Licensee and UNC or any other
Licensor with respect to the amount of the Royalty which is due, or if Licensee
should in any material respect violate or fail to keep or perform any material
covenant, condition, or undertaking of this Agreement on its part to be kept or
performed hereunder, and there is not then occurring any material breach of this
Agreement by any Licensor, then in such event UNC shall have the right, on
behalf of the Licensors, to cancel and terminate this Agreement, and the
Licenses granted by this Agreement, upon thirty (30) days prior written notice
to Licensee if Licensee has failed to cure (unless such failure is due to Force
Majeure) such breach within forty-five (45) days of its receipt of written
notice from UNC describing such breach, or within such longer period of time as
may be reasonably necessary to cure such breach if, due to Force Majeure or
regulatory changes, such breach is not reasonably likely to be cured within such
forty-five (45) day period. If Licensee shall commit a material breach of this
Agreement as described in the first sentence of this Section 5.1 more than four
(4) times in any four (4) consecutive calendar years, then UNC shall have the
right, on behalf of the Licensors, to cancel and terminate this Agreement, and
the Licenses granted by this Agreement, upon sixty (60) days prior written
notice to Licensee, without having to permit Licensee the opportunity to cure.
If UNC does not exercise its right of termination within six (6) months of the
later of (a) the date of discovery by any Licensor of the breach which triggered
the loss of Licensee's right to cure under the preceding sentence, or (b) the
date on which the cure for the most recent prior breach was completed, then
Licensee's right to cure shall be automatically reinstated.

      5.2 Alternatively, should Licensee be in breach or default as set forth in
Section 5.1 above, and should UNC be in a position where it could rightfully
terminate this Agreement in accordance with Section 5.1, then in its sole
discretion after seeking the advice of the other Licensors, which advice shall
be given due consideration by UNC, UNC may convert the exclusive Licenses to
non-exclusive Licenses upon giving fifteen (15) days notice of such decision to
Licensee.

                                      -13-
<PAGE>

      5.3 If Licensee should be adjudged bankrupt or enter into a composition
with or assignment for the benefit of its creditors, then in such event the
Licensors shall, subject to bankruptcy law and the rulings of the bankruptcy
court, have the right to cancel and terminate this Agreement, and the Licenses
herein provided for, upon thirty (30) days prior written notice to Licensee.

      5.4 Any sublicense agreements entered into by Licensee under this
Agreement which are in effect at the time of any termination (for any reason) or
expiration of this Agreement shall continue in full force and effect and shall
be assigned by Licensee to the Licensors, effective as of the date of
termination or expiration, as the case may be, of this Agreement.

      5.5 Any termination or cancellation under any provision of this Agreement
shall not relieve Licensee of its obligation to pay (a) any Royalty or other
fees (including attorney's fees pursuant to Section 3.1 hereof) due or owing at
the time of such cancellation or termination, or (b) any payment due to the
Licensors under Section 6.1 hereof.

      5.6 Unless terminated sooner under the provisions of this Agreement, this
Agreement will continue in full force and effect until the last patent included
in the Patent Rights has expired or been finally held (by a court of competent
jurisdiction) to be invalid or unenforceable.

      5.7 Licensee may, at any time, terminate this Agreement upon six (6)
months written notice to UNC provided that Licensee continue to perform in good
faith its obligations hereunder through the termination date and cooperate with
UNC to permit UNC to continue the commercialization efforts with respect to the
Foundation Program.

      5.8 Within thirty (30) days of the termination of this Agreement under
Sections 5.1 or 5.3, Licensee shall provide to the Licensors copies of all
market clearance applications associated with regulatory approval of Licensed
Products (including all data thereto) and all data related to as yet unfiled
market clearance applications associated with regulatory approval of Licensed
Products. The Licensors shall promptly reimburse Licensee for its reasonable
costs and expenses in complying with this Section 5.8. Licensee shall grant to
the Licensors a non-exclusive worldwide royalty-free right and license to use
all such applications and data for all purposes.

      5.9 Upon the written request of UNC following any termination of this
Agreement under Sections 5.1 or 5.3, Licensee shall return to UNC, on behalf of
the Licensors, or destroy as directed by UNC, on behalf of the Licensors, all
information, data, and any relevant materials provided to Licensee during the
term of this Agreement which are covered by any of the Patent Rights. Licensee
shall provide UNC with a written statement signed by an authorized
representative of Licensee stating that the same has been so delivered or
destroyed, whichever is appropriate. Notwithstanding the foregoing, Licensee
shall be allowed to (a) retain one copy of such information, data and materials
provided to Licensee for purposes of documenting its obligations under this
Agreement, and (b) retain up to three (3) additional copies of such information,
data and materials in order to enable Licensee to continue with its business
operations with respect to products which are no longer covered by any Patent
Rights of the Licensors.

                                      -14-
<PAGE>

5.10 Notwithstanding any other provision of this Agreement, if Licensee does not
satisfy its obligations to continue to make payments to UNC (for the benefit of
the Licensors) after the Effective Date as set forth under Section 3(d) (last
sentence only, as amended) of the 1997 Agreement, then UNC may (on behalf of the
Licensors) deliver to Licensee a notice stating Licensee's failure to satisfy
such obligations. Licensee shall have thirty (30) days from its receipt of such
notice to cure such failure. If Licensee shall fail to cure such failure within
such thirty (30) day period, then UNC may (on behalf of the Licensors) deliver a
notice to Licensee stating the Licensors' election to rescind this Agreement and
the 1997 Agreement effective as of a date specified in such notice, such date to
be no earlier than ten (10) days after the date of delivery of such election
notice.

6.    Disposition of Licensed Products On Hand Upon Cancellation or
      Termination

      6.1 Upon cancellation or termination of this Agreement other than as
provided in Section 5.4, Licensee shall provide UNC with a written inventory of
all Licensed Products in process of manufacture, in use or in stock. Licensee
shall have the privilege of disposing of the inventory of such Licensed Products
within a period of one hundred and eighty (180) days of such termination upon
conditions most favorable to UNC that Licensee can reasonably obtain; provided,
however, that Licensee pay to UNC (for the benefit of the Licensors) a Royalty
or any other payment due thereon as calculated in accordance with Article 3.
Licensee will also have the right to complete performance of all contracts
requiring use of either University Technology, Patent Rights (except in the case
of termination pursuant to Section 5.1), Future Compounds, the Licenses, or
Licensed Products within and beyond said 180-day period; provided, however, that
Licensee pay to UNC (for the benefit of the Licensors) a Royalty or any other
payment due thereon as calculated in accordance with Article 3. If the remaining
term of any such contract exceeds one (1) year, then (a) such contract shall
continue in full force and effect, (b) the Licenses granted hereunder shall
remain in effect solely for the purpose of enabling Licensee to fulfill its
obligations under such contract, (c) Licensee shall no longer be permitted to
enter into any additional contracts requiring the use of any University
Technology, Patent Rights, Future Compounds, Licenses, or Licensed Products, and
(d) Licensee shall, after such one (1) year period, forward to UNC one hundred
percent (100%) of any receipts (other than reimbursement of Licensees expenses
or any indemnification payments) that Licensee thereafter receives under such
contract for the period after such one (1) year period. All Licensed Products
which are not disposed of as provided above shall be delivered to UNC or
otherwise disposed of, in UNC's sole discretion, and at Licensee's sole expense.

7. Use of the Names of the Licensors

      7.1 The use of the name of the Licensors, or any contraction thereof, in
any manner in connection with the exercise of the Licenses is expressly
prohibited except with prior written consent of UNC (on behalf of the Licensor
whose name is requested to be used); provided, however, that no such consent
shall be required for Licensee to identify the Licensors and describe its
relationship and transactions with the Licensors in connection with (a)
communications and filings with the Securities and Exchange Commission, the
NASD, NASDAQ, the Food and Drug Administration, or other governmental or
regulatory agencies or authorities, as reasonably advisable in connection with
or required by such agencies or authorities, (b) the inclusion of the
Descriptive Statement attached hereto as Exhibit B in any

                                      -15-
<PAGE>

communications or other documentation relating to any financing or fund-raising
by Licensee, and (c) the preparation of Licensee's financial statements. In
preparing any such description, Licensee shall not make any claims or statements
that any Licensor has endorsed any product or product candidate of Licensee,
without the prior written consent of UNC (on behalf of such Licensor).

      7.2 Duke University may, without express prior written consent of the
other parties to this Agreement, issue an announcement of the execution of this
Agreement, containing only the names of the inventors of the Patent Rights and
the name of Licensee and the names of the other Licensors, in the Duke Dialogue
and in other internal reports and publications.

      7.3 Neither Licensee, any Affiliate or sublicensee of Licensee, nor any
Licensor (each of all of the foregoing, a "Relevant Party") shall, individually
or collectively, without the express, prior written consent of the appertaining
Relevant Party, (a) use, unless otherwise permitted in this Agreement, in either
advertising, publicity, press release, promotional activity, or other similar
activity, the name or image of (i) such appertaining Relevant Party or any of
its employees, officers, directors, students, or agents, or (ii) any
trade-names, trademarks, trade devices, service marks, symbols or any
abbreviation, contraction or simulation thereof, which is owned by such
appertaining Relevant Party, or (b) make any representations, either directly or
indirectly, about any product or service of any one or more Relevant Parties.

      7.4 If any Relevant Party desires to make any use or representation which
is restricted pursuant to Section 7.3 above, then such Relevant Party shall
request the written consent of the appertaining Relevant Party and submit to
such appertaining Relevant Party a copy of the proposed use or representation.
The appertaining Relevant Party shall use its commercially reasonable efforts to
respond to the requesting Relevant Party within ten (10) days of its receipt of
the copy of such proposed use or representation from the requesting Relevant
Party.

8.    Licensors' Use

      8.1 It is expressly agreed that, notwithstanding any provisions herein,
each Licensor is free to use its University Technology, Patent Rights and
Licensed Products for its own research, public service, clinical, teaching and
educational purposes without payment of royalties; provided, however, that no
Licensor shall sell or distribute any Patent Rights or Licensed Products (or any
University Technology on an exclusive basis) for commercial use or benefit, nor
shall any Licensor donate any Licensed Products for use in any market in which
Licensee is selling such Licensed Product or any competing Licensed Product.
Furthermore, the Licensors shall be free to publish and publicly disclose at
scientific meetings University Technology, as they see fit; provided, however,
that if any such University Technology is not protected by any Patent Rights,
then any Licensor desiring to publish or disclose such University Technology
shall (a) notify Licensee in writing of its intent to so publish or disclose,
providing with such notice a copy of the proposed publication or disclosure for
Licensee's review, and (b) provide Licensee with a reasonable time period (for
which the Licensors shall use commercially reasonable efforts to provide ninety
(90) days, but which shall not be less than forty-five (45) days in any case) to
arrange for the filing, prior to any such publication or disclosure by such
Licensor, of a patent application covering such University Technology as
provided in Article 9.

                                      -16-
<PAGE>

9.    Patents and Infringements

      9.1 Each of the Licensors and Licensee shall each cooperate in good faith
with each other to obtain, maintain and defend any and all of the Patent Rights.
Licensee shall continue to bear the cost of filing, prosecuting, maintaining and
defending all U.S. and foreign patent applications and patents included within
the Patent Rights. Licensee shall reimburse all amounts due pursuant to this
Section 9.1 within thirty (30) days of its receipt of an invoice therefor from
UNC. Such filings and prosecutions shall be (a) in the name or names of the
Licensors employing the inventors of a particular invention, as defined under
patent law, and (b) by experienced patent counsel chosen by UNC. UNC shall keep
Licensee advised on a timely basis as to the prosecution of such applications
and shall, shortly after the execution and delivery of this Agreement, instruct
its patent counsel in writing to deliver to Licensee, on a timely basis, copies
of all correspondence and other documents (including, but not limited to,
Applications, Office Actions, responses, etc.) which are received by or sent by
such patent counsel and which relate to any Patent Right (including, without
limitation, all patents and patent applications included, or to be included,
within the Patent Rights). Licensee shall have the right to advise UNC as to
such prosecution, and further, shall have the right to make reasonable requests
as to the conduct of such prosecution. Licensee shall have the right to directly
access Licensors' patent counsel to facilitate the filing, prosecuting,
maintaining and defending of all U.S. and foreign patent applications and
patents included within the Patent Rights. All final decisions pertaining to the
prosecution of all patents and patent applications included in the Patent Rights
shall be at the sole discretion of UNC, on behalf of the Licensors. Licensee
shall notify UNC at least ninety (90) days prior to any statutory deadlines for
responding to office actions, filing additional applications, and similar
matters, or within forty-five (45) days after receiving notice from UNC of any
deadline if the statutory deadline is ninety (90) days or less after receipt of
such notice from UNC, as to what steps it would like UNC to take. UNC shall,
shortly after the execution and delivery of this Agreement, instruct its patent
counsel in writing that in the event of any dispute between Licensee and either
UNC or any other of the Licensors with respect to any patent, patent application
or other Patent Right, such counsel shall deliver to Licensee, on a timely
basis, upon written request from Licensee, and at Licensee's expense, a copy of
any documents requested by Licensee which are relevant to the patent matter
which is the subject of such dispute, excluding, however, any documents
protected by the attorney-client privilege.

      9.2 As regards foreign patent applications corresponding to the U.S.
patent applications described in Section 9.1 above, Licensee shall designate at
least ninety (90) days prior to any statutory deadline that country or those
countries, if any, in which Licensee desires such corresponding patent
application(s) to be filed. Licensee shall pay all costs and legal fees
associated with the preparation, filing, prosecution and maintenance of such
designated foreign patent applications and such applications shall be in the
name or names of the Licensors employing the inventors of a particular
invention, as defined under patent law. The Licensors may elect to file
corresponding patent applications in countries other than those designated by
Licensee. If the Licensors elect to do so and Licensee does not agree, within
thirty (30) days of receiving notice from UNC of such election by the Licensors,
to pay all costs and legal fees associated with the filing of such corresponding
patent applications in the non-designated countries, then the individual
Licensors exercising such right shall be responsible for all costs and legal
fees associated with the filing of such corresponding patent applications in
such non-designated countries. In such event, Licensee shall forfeit its rights
under the Licenses to the

                                      -17-
<PAGE>

Patent Rights associated with such corresponding patent applications in the
non-designated country(ies) where the Licensors exercise their option to file
such corresponding patent applications.

      9.3 If the production, sale or use of Licensed Products under this
Agreement by Licensee results in any claim for patent infringement against
Licensee, then Licensee shall promptly notify UNC thereof in writing, setting
forth the facts of such claim in reasonable detail. As between the parties to
this Agreement, Licensee shall have the first and primary right and
responsibility at its own expense to defend and control the defense of any such
claim against Licensee, by counsel of its own choice. It is understood that any
settlement of any such claim or action must be approved by each Licensor which
owns any patent or patents involved in the dispute if the validity or
enforceability of such patent or patents will be affected by the settlement or
if such settlement includes a grant of any rights to either any Patent Rights
with respect to such patent or patents or to any University Technology owned by
such Licensor. Such approval shall not be unreasonably withheld or delayed. The
grant of any rights to any Patent Rights or to any University Technology without
providing for commercially reasonable payments from the grantee, including
royalties on sales of product(s) based in whole or in part, manufactured or used
in accordance with any Patent Rights or University Technology, will constitute
sufficient grounds for the Licensors to withhold their approval of such
settlement. The Licensors who own the patent or patents involved shall also have
the right to review and provide input on any other settlement, which input shall
be considered in good faith by Licensee. If any settlement or other resolution
of such claim or action results in a cross-licensing arrangement between
Licensee and the complaining party, then any payments received by Licensee under
such arrangement shall be treated as if they were a non-royalty payment received
by Licensee under a sublicense agreement, and they shall be subject to the
provisions of Section 3.6. The Licensors agree to cooperate with Licensee in any
reasonable manner (including, without limitation, providing evidence and
witnesses (including the inventors) within their control) which may reasonably
be expected to be necessary or advisable in defending against any such action or
negotiating any settlement of such action. Licensee shall reimburse the
Licensors for any reasonable and actual out-of-pocket expenses incurred in
providing such assistance; provided, however, that reimbursement of any expense
of $2,500 or more shall require the submission to Licensee of third-party
invoices for such expenses.

      9.4 In the event that any Patent Rights licensed to Licensee are infringed
by a third party, Licensee shall have the primary right, but not the obligation,
to institute, prosecute and control any action or proceeding with respect to
such infringement, by counsel of its choice, including any declaratory judgment
action arising from such infringement, and Licensee shall bear all expenses for
such action or proceeding and shall be entitled to the entire amount of any
settlement or judgment paid by the third party; provided, however, that if any
part of any settlement or judgment is stated to be compensation to Licensee for
lost sales of a Licensed Product, then Licensee shall pay to UNC on behalf of
the Licensors the appropriate Royalty on such part of the settlement or
judgment. The Licensors agree to cooperate with Licensee in any reasonable
manner which may reasonably be expected to be necessary or advisable in
connection with any such action or proceeding, including, without limitation,
allowing Licensee to institute and maintain the action or proceeding in the name
of the Licensor(s) who owns the patent(s) which are infringed, providing
evidence and witnesses (including the inventors) within its control, performing
such other acts as Licensee may reasonably request, and executing,

                                      -18-
<PAGE>

verifying, and delivering such documents as are needed or as Licensee may
reasonably request. Licensee shall reimburse the Licensors for any and all
commercially reasonable out-of-pocket expenses incurred in providing such
assistance upon submission to Licensee of third-party invoices for such
expenses.

      9.5 Notwithstanding the foregoing, and in the Licensors' sole discretion,
the Licensors who own the Patent Rights that are the subject of a legal action
involving the Future Compounds shall be entitled to participate in such action
through counsel of their own choosing. Nothing in the foregoing sections shall
be construed in any way which would limit the authority of the Attorney General
of North Carolina.

      9.6 All Licensed Products (and/or their containers, labels, and/or other
packaging) sold in the United States shall be marked with all applicable United
States patent numbers. All Licensed Products (and/or their containers, labels,
and/or other packaging) shipped to or sold in other countries shall be marked in
such a manner as to conform with the patent laws and practice of the country of
manufacture or sale.

10.   Waiver

      10.1 It is agreed that no waiver by any party hereto of any breach or
default of any of the covenants or agreements herein set forth shall be deemed a
waiver as to any subsequent and/or similar breach or default. Any and all
waivers must be expressly stated in writing signed by the party granting any
such waiver.

11.   License Restrictions

      11.1 It is agreed that the rights and privileges granted to Licensee are
each and all expressly conditioned upon the faithful performance on the part of
the Licensee of every requirement herein contained, and that each of such
conditions and requirements may be and the same are specific License
restrictions.

12.   Assignments

      12.1 This Agreement is binding upon and shall inure to the benefit of the
Licensors, their successors and assigns. However, this Agreement shall be
personal to Licensee and it is not assignable by Licensee to any other entity
without the express prior written consent of UNC, which consent shall not be
withheld or delayed unreasonably; provided, however, that Licensee may, without
such consent, assign this Agreement to (a) any of its Affiliates, and (b) any
Person acquiring all or substantially all of Licensee's assets.

13.   Indemnity

      13.1 Licensee agrees to indemnify, hold harmless and defend the Licensors,
their trustees, officers, employees, students, and agents, against any and all
claims, suits, losses, damage, costs, fees, and expenses asserted by third
parties, both government and private, resulting from or arising out of the
exercise of the Licenses by Licensee, except to the extent that any such claim,
suit, loss, damage, cost, fee, or expense is attributable to any negligence or

                                      -19-
<PAGE>

intentional misconduct of any Licensor, any inventor, or any trustee, officer,
employee, student or agent of any Licensor or any inventor.

14.   Insurance

      14.1 Licensee shall maintain in force at its sole cost and expense, with
reputable insurance companies, general liability insurance and products
liability insurance coverage in an amount reasonably sufficient to protect
against liability under Section 13.1, above. UNC shall have the right to request
copies of customary policy documents which evidence such coverage, in order to
ascertain from time to time that such coverage exists, such right to be
exercised in a reasonable manner.

15.   Independent Contractor Status

      15.1 No party hereto is an agent of the other for any purpose except as
expressly set forth in (a) this Agreement, (b) the Patent Plan executed by the
Licensors on July 26, 1994, and (c) the Inter-Institutional Agreement dated
January 15, 1997, among the Licensors.

16.   Late Payments

      16.1 In the event Royalty payments or fees are not received by UNC when
due, and there is not a dispute between Licensee and UNC or any other Licensor
with respect to the amount of the Royalty which is due, then Licensee shall pay
to UNC interest at an annual rate (the "Late Rate") equal to the prime rate (as
quoted in the Wall Street Journal) plus two percent (2%) on the amount of
Royalties or fees which are past due. The payment of such interest shall not
foreclose the Licensors from exercising any other rights they may have under
this Agreement as a consequence of the lateness of any payment.

17.   Warranties

      17.1 The Licensors make no warranties that any patent will be issued on
University Technology or Future Compounds. To the best knowledge of each of the
Licensors, the patents comprising the Patent Rights held by such Licensor are
valid and enforceable. The Licensors further make no warranties, express or
implied, as to any matter whatsoever, including, without limitation, the
condition of any invention(s) or product(s), that are the subject of this
Agreement; or the merchantability or fitness for a particular purpose of any
such invention or product. The Licensors shall not be liable for any direct,
consequential, or other damages suffered by Licensee resulting from the use of
the Future Compounds or Licensed Products, except (a) to the extent that any
such damage is attributable to any patent infringement, negligence or
intentional misconduct of any Licensor, any inventor, or any officer, employee,
student or agent of any Licensor or any inventor, and (b) to the extent that
such Licensor may be held liable for such infringing, negligent or intentional
act.

      17.2 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER
THE LICENSORS, NOR THEIR RESPECTIVE TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES,
STUDENTS AND/OR AFFILIATES MAKE ANY REPRESENTATIONS OR EXTEND ANY WARRANTIES OF
ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF

                                      -20-
<PAGE>

MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENT RIGHTS
CLAIMS, ISSUED OR PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER
OR NOT DISCOVERABLE. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A
REPRESENTATION MADE OR WARRANTY GIVEN BY THE LICENSORS THAT THE PRACTICE BY
LICENSEE, ITS AFFILIATES, AND/OR SUBLICENSEES OF THE LICENSES GRANTED HEREUNDER
SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY. IN NO EVENT SHALL THE
LICENSORS, OR THEIR RESPECTIVE TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES,
STUDENTS AND/OR AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF
ANY KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS,
REGARDLESS OF WHETHER THE LICENSORS SHALL BE ADVISED, SHALL HAVE OTHER REASON TO
KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF SUCH DAMAGES.

18.   Accounting and Records

      18.1 Licensee will keep complete, true and accurate books of account and
records for the purpose of showing the derivation of all amounts payable to the
Licensors through UNC under this Agreement. Such books and records will be kept
at Licensee's principal place of business for at least three (3) years following
the end of the calendar quarter to which they pertain, and will be open at all
reasonable times during normal business hours for inspection by a representative
of UNC for the purpose of verifying Licensee's Royalty statements, or Licensee's
compliance in other respects with this Agreement. The representative will be
obliged to treat as confidential all relevant matters and shall, if requested by
Licensee, execute an appropriate confidentiality and non-disclosure agreement.

      18.2 Such inspections shall be at the expense of the Licensors, unless a
variation or error resulting in an underpayment of Royalties of at least the
greater of (a) U.S. $10,000, or the equivalent in foreign currency, or (b) one
point five percent (1.5%) of the total amount of Royalties due for the period
during which the variation or error was in effect, is discovered in the course
of any such inspection, whereupon all costs relating thereto shall be paid by
Licensee.

      18.3 Licensee will promptly pay to UNC the full amount of any Royalty
underpayment, together with interest thereon at the Late Rate; provided,
however, that such Royalty underpayment is not subject to a dispute between
Licensee and UNC or any other Licensor with respect to the amount of the Royalty
which is due.

19.   Compliance with Laws

      19.1 In exercising its rights under the Licenses, Licensee shall fully
comply with the requirements of any and all applicable laws, regulations, rules
and orders of any governmental body having jurisdiction over the exercise of
rights under the Licenses. Licensee further agrees to indemnify and hold the
Licensors and their respective trustees, officers, employees and agents harmless
from and against any costs, expenses, attorney's fees, citations, fines,
penalties and liabilities of every kind and nature which are imposed by reason
of any established violation of any such laws, order, rules and/or regulations,
except to the extent that any of such violation or any of such costs, expenses,
attorney's fees, citations, fines, penalties or liabilities is attributable

                                      -21-
<PAGE>

to the negligence or intentional misconduct of any Licensor, any inventor, or
any trustee, officer, employee, student or agent of any Licensor or inventor.

20.   U.S. Manufacture

      20.1 The parties hereto agree that any Licensed Products sold in the
United States shall be substantially manufactured in the United States.

21.   Notices

      21.1 Any payment or notice required or permitted to be given to the
parties hereto shall be deemed to have been properly given if (a) delivered in
person, (b) delivered by a reputable overnight delivery service which records
the name of the individual accepting delivery (such as, for example, FedEx, DHL,
Airborne Express, UPS, or USPS Express or Priority Mail), (c) mailed by
first-class certified or registered mail, return receipt requested, or (d)
delivered by successful telecopier transmission, with a hard copy of such
transmission delivered in the manner specified in the preceding clauses (a), (b)
or (c), in each case to the other party or parties at the appropriate address or
telecopier number as set forth below or to such other addresses or telecopier
numbers as may be designated by notice to each of the other parties hereto from
time to time during the term of this Agreement. Notices shall be deemed received
on the date on which they are actually delivered to the recipient (in the case
of telecopier transmission, the date of delivery shall be the date of
transmission, if transmitted prior to 5:30 P.M. in the time zone of the
recipient, else the next business day after transmission).

            If to any of the Licensors, to:

                  The University of North Carolina at Chapel Hill
                  Office of Technology Development
                  CB #4105, 308 Bynum Hall
                  Chapel Hill, North Carolina  27599-4105
                  Telephone No.:  (919) 966-3929
                  Telecopier No.:  (919) 962-0646
                  Attn.:  Director

            with copies to:

                  Auburn University
                  Office of Technology Transfer
                  309 Samford Hall
                  Auburn, Alabama  36849-5176
                  Telephone No.:  (334) 844-4977
                  Telecopier No.:  (334) 844-5963
                  Attn.:  Ms. Jan Thornton
                          Director

                                      -22-
<PAGE>

            and to:

                  Duke University
                  Office of Science and Technology
                  454 Davison Building
                  Box 3664 DUMC
                  Durham, North Carolina 27710
                  Telephone No.: (919) 681-6412
                  Telecopier No.: (919) 684-4595
                  Attn.: Dr. Linda F. Abruzzini, Ph.D.
                         Director, Research Resources and Patent Administration

            and to:

                  Georgia State University Research Foundation, Inc.
                  University Plaza
                  Georgia State University
                  Atlanta, Georgia  30303
                  Telephone No.:  (404) 651-2569
                  Telecopier No.:  (404) 651-2846
                  Attn.:  Mr. John D. Marshall, Jr.

            If to Licensee, to:

                  Immtech Pharmaceuticals, Inc.
                  150 Fairway Drive, Suite 150
                  Vernon Hills, Illinois  60061
                  Telephone No.:  (847) 573-0033
                  Telecopier No.:  (847) 573-8288
                  Attn.:  Mr. T. Stephen Thompson
                          President & Director

            with copies to:

                  Immtech Pharmaceuticals, Inc.
                  One North End Avenue, Suite 1111
                  New York, New York  10282
                  Telephone No.:  (212) 791-2888
                  Telecopier No.:  (212) 791-2917
                  Attn.:  Dina Grinshpun, Esq.

                                      -23-
<PAGE>

            and to:

                  Cadwalader, Wickersham & Taft LLP
                  One World Financial Center
                  New York, New York  10281
                  Telephone No.:  (212) 504-6000
                  Telecopier No.:  (212) 504-6666
                  Attn.:  John F. Fritts, Esq.

22.   Governing Laws

      22.1 This Agreement shall be interpreted and construed in accordance with
the laws of the State of North Carolina.

23.   Complete Agreement

      23.1 It is understood and agreed between the Licensors and Licensee that
this Agreement constitutes the entire agreement, both written and oral, between
the parties as to the licensing of the Future Compounds (and the Current
Compounds, if covered under this Agreement pursuant to Section 26.1), and that
all prior agreements relating to the Future Compounds (or the Current Compounds,
if covered under this Agreement pursuant to Section 26.1), either written or
oral, expressed or implied, shall be abrogated, canceled, and are null and void
and of no effect to the extent that they apply to the Future Compounds (and/or
the Current Compounds, if covered under this Agreement pursuant to Section
26.1). Notwithstanding the foregoing, the provisions of (a) Section 3(c),
Section 3(d) (last sentence only, as amended), and Section 5(b) of the 1997
Letter Agreement, (b) Section 1 of the Second Amendment, and (c) Section 2 of
the Third Amendment, are all incorporated by reference into this Agreement as if
fully set forth herein, except to the extent that they confer any rights,
responsibilities or obligations upon Pharm-Eco.

      23.2 Notwithstanding any other provision of this Agreement, Section 6 of
the 1997 Letter Agreement is incorporated by reference into this Agreement as if
fully set forth herein, except to the extent that it confers any rights,
responsibilities or obligations upon Pharm-Eco, subject to the following
additional provisions: Should Licensee fail to execute, within ninety (90) days
of the Effective Date, a Registration Rights Agreement in accordance with
Section 6 of the 1997 Letter Agreement (the "Registration Agreement"), then the
Licensors shall have the option to require Licensee to repurchase a portion of
the Licensee Common Stock issued to the Licensors pursuant to the 1997 Letter
Agreement, with the number of shares to be repurchased to be determined by the
Licensors in their sole discretion but not to exceed ten percent (10%) of the
Licensee Common Stock issued to the Licensors pursuant to the 1997 Letter
Agreement. The Licensors shall be entitled to exercise such option at any time
up until Licensee executes the Registration Agreement, and the repurchase price
paid by Licensee shall be an average of the published NASDAQ daily trading price
for the Licensee Common Stock over the ten trading days preceding the date on
which the Licensors deliver to Licensee written notice of their exercise of the
option.

                                      -24-
<PAGE>

      23.3 Notwithstanding any other provision of this Agreement, the Clinical
Research Subcontract (and all of its exhibits) is incorporated by reference into
this Agreement as if fully set forth herein.

24.   Severability

      24.1 In the event that a court of competent jurisdiction holds any
provision of this Agreement to be invalid, such holding shall have no effect on
the remaining provisions of this Agreement, and they shall continue in full
force and effect.

25.   Rights to Appoint Representatives

      25.1 UNC is entitled, during the term of this Agreement, to designate (by
written notice to Licensee) one appropriate person as a non-voting observer (the
"Observer") of all meetings and other proceedings of Licensee's Board of
Directors. Licensee will provide to the Observer notice of all meetings of the
Board of Directors and a copy of all materials circulated among Licensee's
directors. The Observer and UNC shall be required, if requested by Licensee, to
execute an appropriate confidentiality and non-disclosure agreement covering
confidential information of Licensee; provided, however, that any such
confidentiality and non-disclosure agreement shall allow the Observer and UNC to
disclose such information to the other Licensors if such other Licensors first
agree in writing (and deliver such writing to Licensee) to become a party to
such agreement and to be bound by all of the terms and provisions of such
agreement as if they were an original party thereto.

26.   Applicability to Current Compounds

      26.1 This Agreement and the Licenses shall be applicable to Current
Compounds, in addition to Future Compounds, upon the execution and delivery of
this Agreement. The parties hereto acknowledge the fact that that certain
License Agreement dated August 25, 1993, between UNC and Pharm-Eco (the
"Pharm-Eco License Agreement"), has previously been assigned, in its entirety,
to Licensee by Pharm-Eco. Upon the execution and delivery of this Agreement, (a)
each occurrence of the words "Future Compounds" (excluding the definition of
Future Compounds) shall be deemed to read as "Future Compounds and/or Current
Compounds" unless the context clearly indicates otherwise, (b) the definition of
"Patent Rights" set forth in this Agreement shall also include everything
contained within the definition of "Patent Rights" set forth in the Pharm-Eco
License Agreement, (c) the definition of "University Technology" set forth in
this Agreement shall also include everything contained within the definition of
"University Technology" set forth in the Pharm-Eco License Agreement, (d) this
Agreement shall supercede and serve in lieu of the Pharm-Eco License Agreement
with respect to all Current Compounds, and (e) the Pharm-Eco License Agreement
shall be hereby terminated in all respects and shall no longer be of any effect
whatsoever, and neither party thereto shall have thereunder any obligations of
any kind to the other.

27.   Confidentiality and Non-Disclosure of Information

      27.1 Each of the Licensors, on the one hand, and Licensee, on the other
hand, agrees to accept and maintain the other's information, data, know-how,
samples and other disclosures hereunder or in connection with activities related
to this Agreement (collectively, "Information")

                                      -25-
<PAGE>

on a confidential basis for a period of five (5) years from the date of each
such disclosure. The obligations of this Article 27 shall survive and continue
for three (3) years after the expiration or any termination of this Agreement.
Specifically excluded from such confidential treatment shall be Information
which: (a) at the time of disclosure to the receiving party, was already
published, known publicly, or otherwise in the public domain; (b) after
disclosure to the receiving party, is published, becomes known publicly, or
otherwise becomes part of the public domain through no fault or breach of the
receiving party or any of its Affiliates; (c) the receiving party can establish
was in its possession prior to the time of disclosure to it; or (d) after
disclosure by the disclosing party, is made available to the receiving party in
good faith by a third party having no obligation of confidentiality to the
disclosing party. UNC shall be permitted to disclose Information to the
Foundation as necessary to comply with the terms of the Foundation Program,
however, to the extent required by federal securities laws or other federal or
state law, UNC shall not disclose material non-public information prior to
receiving Immtech consent.

28.   Arbitration

      28.1 If there shall arise in the future any dispute between any of the
parties hereto arising out of or relating to this Agreement, such as is
contemplated by Section 3.6(b) with respect to Future Duke Licensed Products, or
to any aspect of the Licenses granted by this Agreement, the parties hereto
agree that if the parties to such dispute agree at such future time to submit
such dispute to arbitration, then such arbitration shall be a confidential and
binding arbitration before a tribunal under the Commercial Arbitration Rules of
the American Arbitration Association, and shall be held at a site mutually
agreeable to the parties to the arbitration. If the parties are unable to agree
upon a site, then the site shall be selected by the arbitration tribunal. The
arbitration tribunal shall consist of three (3) arbitrators. The party
requesting arbitration shall name an arbitrator selected by it in its request
for arbitration. The responding party shall name an arbitrator selected by it in
its answer or response to such request for arbitration. The two arbitrators so
named shall jointly select a third arbitrator, who shall be the chairman of the
tribunal and who shall have no prior or then existing relationship or business
arrangements or financial dealings with, or interests in, either of Licensee,
UNC or any other Licensor. The decision of the arbitration tribunal shall be
final, and judgment upon the award rendered by the arbitration tribunal may be
entered in any competent court having jurisdiction thereof for judicial
acceptance of such award and an order of enforcement. Each party hereto hereby
submits itself to the courts of the place of arbitration, but only for the entry
of judgment with respect to the decision of the arbitration tribunal. The
parties hereto agree that the arbitration tribunal may, in its sole discretion,
award reasonable costs and attorney's fees to the prevailing party, and may, in
its sole discretion, assess the costs of the arbitration against the
non-prevailing party.

29.   Survival of Terms

      29.1 The provisions of Articles 6, 7, 9.3, 9.4, 9.5, 13, 14, 16, 17, 18,
19, 21, 22, 27, and 28 shall survive the expiration or termination of this
Agreement until the expiration of the appropriate statute of limitations for
such Article, except that Article 6 shall survive until eighteen (18) months
after the expiration or termination of the last contract requiring use of either
University Technology, Patent Rights, Licensed Products, Future Compounds, or
the Licenses.

                                      -26-
<PAGE>

30.   Telecopier Execution and Delivery

      30.1 A facsimile, telecopy or other reproduction of this Agreement may be
executed by one or more parties hereto, and an executed copy of this Agreement
may be delivered by one or more parties hereto by facsimile, telecopy or similar
instantaneous electronic transmission device pursuant to which the signature of
or on behalf of such party can be seen, and such execution and delivery shall be
considered valid, binding and effective for all purposes. At the request of any
party hereto, all parties hereto agree to execute an original of this Agreement
as well as any facsimile, telecopy, or other reproduction hereof.

31.   Counterparts

      31.1 This Agreement may be executed in one or more counterparts, each of
which shall be deemed an original, but all of which, taken together, shall
constitute one and the same instrument. 32. General Representations and
Warranties

      32.1 Each party hereto represents and warrants to the other parties hereto
that (a) the execution and delivery of this Agreement has been duly authorized
and all actions necessary for the due execution and delivery of this Agreement
have been taken, in each case to the extent necessary to make this Agreement
valid and enforceable, and (b) this Agreement constitutes the legal, valid and
binding obligation of such party, and is enforceable against it in accordance
with its terms, and (c) the person signing this Agreement on behalf of such
party has the authority to do so on behalf of such party.

33.   Headings

      33.1 The Article and Section headings contained in this Agreement are for
reference purposes only and shall not affect in any manner the meaning or
interpretation of this Agreement.

    (Remainder of Page Intentionally Left Blank - Signature Page Follows)

                                      -27-
<PAGE>

      IN WITNESS WHEREOF, the Licensors and Licensee have each executed this
Agreement, in duplicate originals, by their respective officers hereunto duly
authorized, as of the day and year first above written.

THE UNIVERSITY OF NORTH CAROLINA            IMMTECH PHARMACEUTICALS, INC.
   AT CHAPEL HILL

By:/s/ Tony G. Waldrop                      By:/s/ Eric L. Sorkin
   ----------------------------------          ---------------------------------
   Tony G. Waldrop                             Eric L. Sorkin
   Vice Chancellor for Research and            Chief Executive Officer
       Graduate Studies

GEORGIA STATE UNIVERSITY                    AUBURN UNIVERSITY
RESEARCH FOUNDATION, INC.

By:/s/ Charles Louis                        By:/s/ Michael Moriarty
   ---------------------------------           ---------------------------------
   Charles Louis                               Michael Moriarty
   Chairman                                    Associate Provost and Vice
                                               President for Research

DUKE UNIVERSITY

By:/s/ Robert L. Taber
   ------------------------------------
   Robert L. Taber
   Vice ChancellorEXHIBIT 10.2

              AMENDED AND RESTATED CLINICAL RESEARCH SUBCONTRACT

      This Amended and Restated Clinical Research Subcontract, dated and
effective as of March 28, 2006 (this "Agreement"), is entered into by and
between The University of North Carolina at Chapel Hill for its School of
Medicine, (hereinafter called "UNC-CH"), and Immtech Phamaceuticals, Inc., a
Delaware corporation with its principal office and place of business at 150
Fairway Drive, Suite 150, Vernon Hills, IL 60061, (hereinafter called
"Immtech"). Capitalized terms used but not defined herein shall have the
meanings ascribed to such terms in the License Agreement (defined in Section
8(C) below).

                               W I T N E S S E T H

      WHEREAS, in pursuit of its educational purposes, which include research
and training, UNC-CH undertakes scholarly research and experimental activities
in a variety of academic disciplines; and

      WHEREAS, a United States non-profit foundation (the "Foundation") awarded
to UNC-CH a grant on November 8, 2000 (the "2000 Foundation Grant") to fund a
research and development program for novel drug candidates for the treatment of
Human African Trypanosomiasis and Lieshmaniasis; and

      WHEREAS, the Foundation Program contemplates that Immtech would perform
certain functions therein; and

      WHEREAS, in furtherance of its scholarly research and instructional
interests, UNC-CH is willing to contract with Immtech upon the terms and
conditions set forth below; and

      WHEREAS, the Foundation Program contemplated by this Agreement is of
mutual interest and benefit to Immtech and to UNC-CH, and will further UNC-CH's
instructional, research and public service objectives in a manner consistent
with its status as an educational institution; and

      WHEREAS, the Research Plan (the "Research") (a copy of which is attached
hereto as Exhibit A), which will guide the performance of this Agreement, has
been written collaboratively by UNC-CH and by Immtech; and

      WHEREAS, Immtech is uniquely equipped to perform the Research; and

      WHEREAS, UNC-CH and Immtech are committed to making products resulting
from the Research available in developing countries; and

      WHEREAS, the parties hereto entered into the original Clinical Research
Subcontract as of March 29, 2001 (the "Original Subcontract"); and

      WHEREAS, the parties hereto are together submitting an application to the
Foundation to request additional funding to continue the Foundation Program,
particularly for the

                                      -1-
<PAGE>

development of DB289 for the treatment of Human African Trypanosomiasis (the
"2006 Foundation Grant", and together with the 2000 Foundation Grant, the
"Foundation Grants"); and

      WHEREAS, the parties hereto have agreed, among other things, to cooperate
and jointly prepare and submit an application for the 2005 Foundation Grant,
which, subject to the award of such 2006 Foundation Grant, would result in an
amendment and supplement to the "Budget And Payment Schedule" attached hereto on
Exhibit B to incorporate the budget and payment schedule included within the
2006 Foundation Grant, when and if awarded.

      NOW THEREFORE, in consideration of the agreements and covenants contained
herein, the sufficiency of which are hereby acknowledged, the parties hereto
hereby agree as follows:

1.    SCOPE OF WORK.

   A. Immtech agrees it is fully able to perform the Research in a professional,
      competent manner with strict adherence to its terms, and Immtech will
      utilize its commercially reasonable and good faith efforts to do so.
      UNC-CH and Immtech further agree that during the term of this Agreement
      they will jointly prepare protocols pursuant to the Research Plan to guide
      clinical trials (the "Protocols").

   B. Immtech shall exercise commercially reasonable and good faith efforts to
      carry out the Research in accordance with this Agreement and in a manner
      that is consistent with and in furtherance of the Grant Objectives and the
      Global Access Plan. Immtech may provide through subcontract for
      performance of portions of the Research by other entities; provided,
      however, that each such subcontract to noncommercial entities shall
      include payment of indirect costs not to exceed ten percent (10%) of the
      total amount of such subcontract, and that the scope of work for each such
      subcontract shall have been approved by UNC-CH in writing before execution
      and delivery of that subcontract.

   C. Immtech and UNC acknowledge that the Foundation requires that products
      made from the Foundation Program funded by the Foundation Grant should be
      made available to the developing countries of the world at a reasonable
      price. To that end, Immtech has developed, and intends to carry out, the
      Global Access Plan attached hereto as Exhibit C.

   D. Research funded by, and New Inventions and Discoveries resulting from, the
      Foundation Program shall be subject to the oversight of a nine member
      "Steering Committee" comprised of representatives from UNC-CH, the
      Foundation and Immtech, and qualified, disinterested third-parties. The
      Steering Committee will be chaired by one of the disinterested third
      parties. The Steering Committee will oversee the timelines and milestones
      for Foundation Program activities, evaluate and recommend contingencies if
      unexpected events arise, oversee compliance with ethical and regulatory
      obligations and generally advise Foundation Program participants with
      regard to implementation of the Global Access Plan attached at Exhibit C
      hereto. A "Project Manager" will be appointed by the Steering Committee to
      coordinate Steering Committee activities, facilitate communications among
      committee members and Foundation Program participants and collate reports
      to the Foundation.

                                      -2-
<PAGE>

      The Scientific Advisory Board (defined below) shall provide to Foundation
      Program participants scientific and medical advice and ensure the review
      of clinical trials and protocols. The Scientific Advisory Panel shall
      coordinate and collaborate with the Steering Committee on any matters
      directed to the Scientific Advisory Panel that would materially alter the
      Foundation Program, a protocol or clinical trial.

2.    PERSONNEL AND STEERING COMMITTEE

   A. Immtech's Principal Investigator is Carol Olson, M.D., together with such
      additional personnel as may be assigned by Immtech. UNC-CH's Principal
      Investigator shall be Richard Tidwell, Ph.D.

   B. Each of UNC-CH, the Foundation and Immtech will appoint members to the
      Steering Committee in the manner set forth in the Global Access Plan.

3.    PERFORMANCE PERIOD.

      The effective period of this Amended and Restated Agreement will commence
on the date the last authorized representative of a party hereto signs this
Agreement (the "Effective Date") and will terminate on the date that the
Research, as the same may be amended or supplemented, is completed, unless the
Agreement is otherwise terminated in accordance with Article 13. The effective
period may be extended by mutual agreement as provided in Article 14.

4.    RECORDKEEPING, REPORTING AND ACCESS.

   A. Subject to the confidentiality provisions contained in Section 6 below,
      UNC-CH's authorized representative(s), representatives of the Foundation,
      and regulatory authorities to the extent permitted by law, may, during
      regular business hours, arrange in advance with Immtech's Principal
      Investigator and Immtech to:

       (1) examine and inspect Immtech's facilities, including labs and trial
          sites required for performance of the Research; and

       (2) inspect and copy all data and work products relating to the Research
          (such copying to be done at the expense of the requesting party if
          more than one copy is requested to be made).

   B. Immtech shall cooperate with any regulatory authority and allow regulators
      access to applicable records and data, including records, accounts, notes,
      reports and data prepared and maintained pursuant to clause 4.C below. In
      performing the Research, Immtech shall abide by the guidelines for
      biomedical research set forth by the Council for International
      Organizations of Medical Sciences.

                                      -3-
<PAGE>

   C. Immtech and its Principal Investigator shall perform the following record
      keeping and reporting obligations in a timely fashion:

       (1) preparation and maintenance of complete, accurately written records,
          accounts, notes, reports and data of the Research; and

       (2) preparation and submission to UNC-CH in a timely manner of a copy of
          all original case report forms ("Case Reports") for each patient or
          subject participating in the Research ("Research Subject") as provided
          in the Protocols.

   D. All data and work products relating to the Research, including data and
      work products developed by subcontractors, shall be jointly owned by
      UNC-CH and Immtech; provided, however, that Immtech may use the data and
      work products generated by the Research in connection with efforts to
      obtain regulatory approval for Immtech products.

5.    COST AND PAYMENT.

   A. As consideration for performance under the terms of this Agreement, and
      subject to continued availability of funds from the Foundation, UNC-CH
      will pay Immtech, as and when received under the Foundation Grants, the
      amounts set forth in the "Budget and Payment Schedule" provided in Exhibit
      B attached hereto and incorporated herein by reference. The budget allows
      for a permissible amount of overhead due any party or entity in compliance
      with the budget approved as part of the Grant Agreements. Funds shall be
      paid by UNC-CH to Immtech as provided herein by wire transfer of
      immediately available funds to the account specified by Immtech below:

                 ---------------------------------------------

                 Bank Name:             LaSalle Bank N.A.
                 ---------------------------------------------
                 Bank ABA No.:          0710-0050-5
                 ---------------------------------------------
                 Immtech Account No.:   5800308586
                 ---------------------------------------------
                 Immtech Tax I.D. No.:  39-1523370
                 ---------------------------------------------
                 Reference:             Foundation Grant
                 ---------------------------------------------

   B. Payment by UNC-CH of all funding owing to Immtech shall be by wire
      transfer to the account set forth above and shall be made to Immtech
      according to the Budget And Payment Schedule. All costs outlined in the
      Budget And Payment Schedule shall remain firm for the duration of the
      Research, unless otherwise agreed herein or in writing by Immtech and
      UNC-CH. Immtech shall deposit funds paid to Immtech in advance of services
      being rendered hereunder in an interest-bearing account, and all interest
      earned thereby shall be paid to UNC-CH on a quarterly basis in arrears,
      with the such payment due not later than thirty days after the end of each
      such quarter in which interest is earned.

   C. Immtech shall maintain records of receipts and expenditures under this
      Agreement for a period of four (4) years following the termination or
      expiration of this Agreement.

                                      -4-
<PAGE>

   D. Funds paid to Immtech pursuant to this Agreement shall only be used for
      the purposes of the Foundation Program.

6.    CONFIDENTIAL INFORMATION.

   A. Subject to UNC-CH's reporting obligations to the Foundation under the
      Grant Agreements, neither Immtech nor UNC-CH shall disclose or use for any
      purpose other than performance of the Research, any and all trade secrets,
      privileged records or other confidential or proprietary information
      (collectively, "Information") disclosed by one party to the other pursuant
      to this Agreement. Such Information shall be disclosed in writing, or if
      disclosed orally or in other than documentary form shall be reduced to
      writing thirty (30) days thereafter. Information which is not in oral or
      written form, such as but not limited to data tapes, shall be designated
      in writing as confidential within thirty (30) days after disclosure. UNC
      shall be permitted to disclose Information to the Foundation as necessary
      to comply with the terms of the Foundation Program, however, to the extent
      required by federal securities laws or other federal or state law, UNC
      shall not disclose material non-public information prior to receiving
      Immtech consent. The obligation of non-disclosure shall not apply to the
      following:

       (1) Information at or after such time that it is or becomes publicly
          available through no fault of the recipient party;

       (2) Information that is already independently known to the recipient
          party, as shown by its prior written records;

       (3) Information at or after such time that it is disclosed on a
          non-confidential basis by a third party with the legal right to do so;
          or

       (4) Information independently developed by personnel of the recipient
          party not involved in the Research and not otherwise privy to the
          Information.

   B. The obligations of confidentiality under this Article shall survive and
      continue for three (3) years after the expiration or termination of this
      Agreement.

   C. In the event that either party shall come into contact with Research
      subjects' medical records, that party shall hold in confidence the
      identity of the patient and shall comply with all applicable law(s)
      regarding the confidentiality of such records.

   D. In the event either party finds it necessary to disclose Information to a
      proper authority to permit such party to defend its research against an
      allegation of fraud or other misconduct in science, then such defending
      party shall first notify the other party, whereupon both Immtech and
      UNC-CH shall cooperate in good faith to reach an agreement with respect to
      a mutually satisfactory way to disclose such Information as necessary for
      this limited purpose.

                                      -5-
<PAGE>

7.    PUBLICATIONS.

      Either party shall have the right to publish the results of Research
provided such publication does not constitute a violation of Article 6. It is
anticipated that Immtech and UNC-CH will coordinate publications. However, in
the event that either party intends to publish independently of the other, prior
to submission for publication or presentation, the party seeking to publish will
provide the other party thirty (30) days for review and comment upon the
manuscript or other material for such publication. Expedited reviews for
abstracts or poster presentations may be arranged if mutually agreeable to
UNC-CH and Immtech or their respective Principal Investigator. Either party
shall be permitted to advise as to the implications of timing of the publication
if the same clinical trials set forth in Protocol are still in progress at other
sites. In addition, if requested in writing and with reasonable justification,
the party proposing to publish will withhold such publication an additional
sixty (60) days to allow for filing a patent application or taking such other
measures as the other party deems appropriate to establish and preserve its
proprietary rights. Notwithstanding the foregoing, the parties agree that if the
Research is part of a multi-center study, then the first publication of the
results of the Research shall be made in conjunction with the results from the
principal investigators at the other study centers. The manner in which the
publication will be generated will be negotiated between UNC-CH, Immtech and the
principal investigators of other study centers prior to initiation of the
relevant clinical trials involved in the Research. However, in the event no
publication of the multi-center study has been made within one year of the
completion of the study at all centers, then Immtech or UNC-CH will be free to
publish its own results.

8.    INTELLECTUAL PROPERTY.

   A. "New Invention or Discovery" shall mean any invention or discovery
      conceived or reduced to practice during and as a part of the Research or
      the Foundation Program (1) performed pursuant to this Agreement by
      Immtech's Principal Investigator, staff, employees, or subcontractors or
      jointly by such an individual or individuals working with one or more
      employees of UNC-CH, or (2) performed by any subcontractors of UNC-CH, or
      their respective investigators (collectively with such subcontractors, the
      "Subcontractors"), at any other study center involved in the Foundation
      Program, or jointly by any such Subcontractor or Subcontractors working
      with one or more employees of UNC-CH.

B.    Immtech shall promptly notify UNC-CH, in writing, of any of its New
      Inventions or Discoveries. The notice shall provide a full written
      description of such New Invention or Discovery.

C.    UNC-CH shall own all right, title and ownership in any New Invention or
      Discovery; provided, however, that any such New Invention or Discovery
      shall be licensed to Immtech under and subject to that certain License
      Agreement dated January 28, 2002 by and among Immtech, UNC-CH, Auburn
      University, Duke University, and the Georgia State University Research
      Foundation, Inc., as the same may be amended, superseded or replaced from
      time-to-time (the "License Agreement").

                                      -6-
<PAGE>

D.    UNC-CH represents and warrants (1) that each of those subcontractors at
      the other study centers involved in the Foundation Program which are
      performing "basic research" (each, a "BR Subcontractor") has granted
      UNC-CH an option, for 180 days after such BR Subcontractor delivers a
      notice to UNC-CH informing UNC-CH of any of its New Inventions or
      Discoveries, to receive an exclusive license for such New Invention or
      Discovery from such BR Subcontractor (the "License Option"), and that each
      such BR Subcontractor may not license any of its New Inventions or
      Discoveries to any other person or entity until either UNC-CH elects to
      not exercise its License Option with respect to such New Invention or
      Discovery, or such 180 day option period expires without UNC-CH having
      exercised its License Option with respect to such New Invention or
      Discovery, (2) that New Inventions or Discoveries are not licensed to
      anyone other than Immtech, and (3) that UNC-CH is not under any obligation
      to license any New Inventions or Discoveries to anyone other than Immtech.
      UNC-CH covenants and agrees that UNC-CH will use its best efforts to
      ensure that each new BR Subcontractor or other subcontractor which UNC-CH
      may engage after the date of this Agreement grants to UNC-CH a License
      Option substantially similar to the License Option described in the
      preceding sentence.

E.    UNC-CH agrees that it will not license or sublicense any New Inventions or
      Discoveries to anyone other than Immtech without Immtech's express prior
      written consent. UNC-CH agrees that it will (1) within ten (10) days after
      its receipt by its Office of Technology Development from any BR
      Subcontractor or other subcontractor of a notice of any New Invention or
      Discovery, forward to Immtech a complete copy of such notice, (2) request
      from such BR Subcontractor any information requested by Immtech, (3) allow
      Immtech up to the 170th day of UNC-CH's 180 day License Option period (or
      up to the tenth (10th) day prior to the deadline for UNC-CH set forth in
      such License Option, if such License Option period is not 180 days) for
      Immtech to deliver a notice to UNC-CH stating whether or not Immtech
      requests UNC-CH to exercise its License Option with respect to such New
      Invention or Discovery, and (4) if so requested by Immtech pursuant to the
      preceding clause, duly exercise its License Option with respect to such
      New Invention or Discovery, and contemporaneously with such exercise,
      sublicense such New Invention or Discovery to Immtech on such terms as are
      as close to the terms of the license granted to UNC-CH as is permitted by
      the terms of such license granted to UNC-CH.

F.    It is agreed that neither UNC-CH nor Immtech transfers to the other by
      operation of this Agreement any patent right, copyright right, or other
      proprietary right of either party, except as specifically set forth
      herein.

G.    Notwithstanding anything to the contrary herein or in the License
      Agreement, Immtech hereby grants to Licensors a non-exclusive, fully paid,
      royalty-free, non-revocable license (with the right to sublicense) to the
      Patent Rights and University Technology for the Foundation Product to the
      extent necessary to permit Licensors to (i) make or have Foundation
      Product made, and (ii) use, offer for sale and sell each Foundation
      Product solely for use in Developing Countries for treatment of Human
      African Trypanosomiasis under the Foundation Program, provided however,
      that Licensors shall not exercise such license unless and until the
      occurrence of any of the following events (a "Licensing

                                      -7-
<PAGE>

      Event"): (i) this Agreement is terminated solely as a result of a breach
      by Immtech (e.g. not due to a breach caused by the Foundation's failure to
      fund the Grant or other breach predicated by or contributed to by UNC-CH
      or the Foundation because of the Foundation's improperly withholding
      funding (based on the terms of the Grant Agreements)) or (ii) Immtech is
      unwilling or fails to fulfill the commitments set forth in Exhibit D
      hereto. A Licensing Event shall not be deemed to have occurred until (x)
      UNC-CH has sent a written demand to Immtech stating that one or more of
      the events listed in this paragraph has occurred and (y) Immtech fails to
      cure such event to the satisfaction of UNC-CH within 90 days thereafter.
      Upon the occurrence of a Licensing Event, Immtech shall provide
      confidentially to Licensor (with any further distribution by Licensor
      subject to similar confidentiality requirements) such information, drug
      product and/or data as is necessary or reasonably desirable to facilitate
      Licensor's further sublicense or distribution of Foundation Products in
      such Developing Countries.

USE OF NAMES IMMTECH, UNC-CH AND FOUNDATION

   A. The use of the name, symbol or any mark of any party hereto or of the
      Foundation, or any contraction or combination thereof, in any manner in
      connection with the Research is expressly prohibited except with prior
      written consent of the entity owning such name, symbol or mark; provided,
      however, that no such consent shall be required for Immtech to identify
      UNC-CH and describe its relationship and transactions with UNC-CH in
      connection with (a) communications and filings with the Securities and
      Exchange Commission, the NASD, NASDAQ, the Food and Drug Administration,
      or other governmental or regulatory agencies or authorities, as reasonably
      advisable in connection with or required by such agencies or authorities,
      (b) the inclusion of any statement previously made available to the
      public, or permitted under the License Agreement or the license agreement
      among Immtech, UNC-CH, Auburn University, Duke University, and the Georgia
      State University Research Foundation, Inc. dated August 25, 1993 (the
      "1993 Agreement"), in any communications or other documentation relating
      to any financing or fund-raising by Immtech, (c) the preparation of
      Immtech's financial statements, and (d) communications with other study
      centers involved in the Foundation Program.

10.   APPLICABLE LAW.

      This Agreement shall be governed by the laws of the State of North
Carolina.

11.   NOTICE.

      Any notice required or permitted under this Agreement shall be in writing
and shall be deemed given as of the date it is (A) delivered by hand, or (B)
delivered by courier or delivery service (including, without limitation, FedEx,
DHL, Airborne Express, UPS, Express Mail and Priority Mail) or by Registered or
Certified Mail, postage prepaid, return receipt requested, or (C) received by
facsimile, in each case addressed to the party to receive such notice at the
address or facsimile number set forth below, or such other address or facsimile
number as is subsequently specified by written notice to the parties hereto:

                                      -8-
<PAGE>

            If to UNC-CH:

                  The University of North Carolina at Chapel Hill:
                  Vice Chancellor for Research and Economic Development
                  The University of North Carolina at Chapel Hill
                  104 Airport Drive, Suite 2200, CB # 1350
                  Chapel Hill, North Carolina  27599-1350
                  Telephone: (919) 966-3411
                  Facsimile:  (919) 962-5011
                  Attn: Tony G. Waldrop

            If to Immtech:

                  Immtech Phamaceuticals, Inc.
                  150 Fairway Drive
                  Suite 150
                  Vernon Hills, IL  60061
                  FAX:  (847) 573-8288
                  Attention:  T. Stephen Thompson

                  with a copy to:

                  Immtech Phamaceuticals, Inc.
                  150 Fairway Drive
                  Suite 150
                  Vernon Hills, IL  60061
                  FAX:  (847) 573-8288
                  Attention:  Dina Grinshpun, Esq.

                  and

                  Cadwalader, Wickersham & Taft LLP
                  One World Financial Center
                  New York, New York  10281
                  FAX: (212) 504-6666
                  Attention: John F. Fritts, Esq.

12.   LIABILITY.

      Immtech hereby agrees to indemnify, defend and hold harmless UNC-CH and
its schools, departments and employees from any and all liability to the extent
that such liability arises out of Immtech's performance of this Agreement or the
performance of its agents, employees or subcontractors. UNC-CH hereby agrees, to
the extent permitted by the North Carolina Tort Claims Act, to indemnify, defend
and hold harmless Immtech and its directors, officers and employees from any and
all liability to the extent that such liability arises out of UNC-CH's

                                      -9-
<PAGE>

performance of this Agreement or the performance of its agents, employees,
professors, researchers, students or subcontractors.

13. TERMINATION OF CLINICAL TRIALS AND/OR THIS AGREEMENT.

   A. Any clinical trial under any Protocol may be terminated by either party,
      upon immediate prior notice, if animal, human, and/or toxicological test
      results or adverse reactions or side effects with the drug administered or
      the device employed in such clinical trial is of such magnitude or
      incidence to support, in the written opinion of the Scientific Advisory
      Board appointed by UNC-CH to oversee the Research, the termination of such
      clinical trial for the specific compound being studied. If such a
      termination occurs, then the parties will evaluate other candidate
      compounds for substitution and will revise the Research and Protocol
      accordingly; provided, however, that if UNC-CH's Principal Investigator
      and Immtech's President cannot reach an agreement on the selection of
      another candidate compound for substitution within sixty (60) days after
      such termination, then Fred Sparling, M.D., or his successor as chairman
      of the Scientific Advisory Board, shall, after consultation with both
      parties and after reviewing relevant data for each candidate compound,
      select the next candidate compound.

   B. This Agreement may be terminated by either party upon thirty (30) days'
      prior written notice if any of the following conditions occurs:

       (1) If either party fails to comply with a material term of this
          Agreement after receipt of written notice with reasonable opportunity
          to cure from the other party; termination under this clause shall only
          be effective when initiated by the non-breaching party.

       (2) If the Foundation withdraws or terminates any Foundation Grant to
          UNC-CH through which UNC-CH is funding the Research.

   C. This Agreement may be terminated in accordance with the following:

       (1) If the License Agreement is terminated due to a breach or default
          thereunder by Immtech, without any successor or replacement agreement
          being entered into to which UNC-CH and Immtech are each a party, then
          each of Immtech and UNC-CH shall have the right, upon written notice
          to the other during the ninety (90) days following the effective date
          of such termination, to terminate this Agreement. If neither Immtech
          nor UNC-CH exercises such right, then this Agreement shall continue in
          accordance with its terms, and any licenses or rights which were
          granted by UNC-CH to Immtech under the License Agreement which are
          necessary or appropriate in order for Immtech to perform its
          obligations under this Agreement shall remain in effect for the
          duration of this Agreement, and shall be governed by the terms and
          provisions of the License Agreement as though such agreement was still
          in effect.

       (2) If Richard Tidwell, Ph.D., were to die, become disabled, leave
          UNC-CH, or otherwise be unable or unwilling to continue his activities
          at UNC-CH in connection with this Agreement, and if Immtech and UNC-CH
          are not able, within six (6)

                                      -10-
<PAGE>

          months after the date of Dr. Tidwell's death, disability, departure or
          other cessation of his activities, to engage a mutually agreeable
          successor to act as the Principal Investigator for UNC-CH hereunder,
          then each of Immtech and UNC-CH shall have the right, upon written
          notice to the other during the ninety (90) days following the end of
          such six (6) month period, to terminate this Agreement. If neither
          Immtech nor UNC-CH exercises such right, then this Agreement shall
          continue in accordance with its terms, and Immtech and UNC-CH shall
          continue to cooperate in good faith to engage a mutually agreeable
          successor to act as the Principal Investigator for UNC-CH hereunder.

   D. Upon the effective date of termination, there shall be an accounting
      conducted by Immtech, subject to verification by UNC-CH. Within thirty
      (30) days after receipt of adequate documentation therefore, UNC-CH will
      make payment to Immtech for:

       (1) all services properly rendered and monies properly expended by
          Immtech until the date of termination not yet paid for; and

       (2) non-cancelable obligations properly incurred for the Research by
          Immtech prior to the effective date of termination; provided, however,
          that such obligations shall not exceed a period of twelve (12) months
          beyond termination of the Agreement (unless UNC-CH shall have
          previously approved such contract or subcontract of longer duration)
          and that in no event shall UNC-CH's obligation to make payment to
          Immtech exceed the amounts budgeted for the project segment under way
          at the time of termination;

       provided, that all such payments are consistent with payments properly
       incurred in connection with the Grant Agreements.

   E. Immtech will credit or return to UNC-CH any Foundation Funds not expended
      or obligated by Immtech in connection with the Research prior to the
      effective termination date of the notice of termination.

   F. Immediately upon receipt of a notice of termination of either this
      Agreement or a clinical trial, Immtech's Principal Investigator shall stop
      enrolling Research Subjects into the Protocol for such clinical trial and
      shall cease conducting procedures on Research Subjects already enrolled in
      the Protocol directed by UNC-CH, to the extent medically appropriate in
      Immtech's discretion. If UNC-CH and Immtech cannot agree on the process
      for winding down such clinical trial, then the matter shall be presented
      to the Scientific Advisory Board for direction. Notwithstanding the
      forgoing, if Immtech elects to take over the funding of the clinical trial
      under way, then (1) Immtech may continue such clinical trial and shall
      have sole discretion over such clinical trial from such point forward, and
      (2) Immtech shall indemnify, defend and hold harmless UNC-CH and its
      schools, departments and employees from any and all liability to the
      extent that such liability arises out of Immtech's continuation of such
      clinical trials from such point forward.

                                      -11-
<PAGE>

   G. Termination of this Agreement by either party shall not affect the rights
      and obligations of the parties accrued prior to the effective date of the
      termination. The rights and duties under Articles 4, 6, 7, 8, 9, 10, 11,
      12, 13, 14 and 21 survive the termination or expiration of this Agreement.

   H. If this Agreement is terminated prior to completion, then Immtech shall
      furnish UNC-CH a reasonably comprehensive Principal Investigator's report
      for the Research completed.

   I. Termination or cancellation of this Agreement for any reason shall not
      affect the rights and obligations of the parties with respect to the
      License Agreement.

14.   AMENDMENTS.

      This Agreement and the Protocol may only be extended, renewed or otherwise
amended by the mutual written consent of parties hereto.

15.   ENTIRE AGREEMENT.

      This Agreement represents the entire understanding of the parties with
respect to the subject matter hereof. In the event of any inconsistency between
this Agreement and the Protocols, the terms of this Agreement shall govern. This
Agreement is subject to and shall be implemented in a manner consistent with the
Grant Agreement documenting the Foundation Program.

16.   SEVERABILITY.

      This invalidity or unenforceability of any term or provision of this
Agreement shall not affect the validity or enforceability of any other term or
provision hereof.

17.   INTEGRATION.

      Exhibits A, B, C and D hereto are incorporated into this Agreement by
reference.

18.   ASSIGNMENT.

   A. Neither party hereto may assign, cede or transfer any of its rights or
      obligations under this Agreement without the written consent of the other
      party, which consent may not be unreasonably withheld; provided, however,
      that without such consent either party may assign this Agreement in
      connection with the transfer or sale of all or substantially all of its
      assets or business to, or its merger or consolidation with, another
      company. Immtech may also assign this Agreement in whole or in part
      without the consent of UNC-CH to any affiliate entity.

                                      -12-
<PAGE>

   B. This Agreement shall insure to the benefit of and be binding upon each
      party signatory hereto, its successors and permitted assigns. No
      assignment shall relieve either party of the performance of any accrued
      obligation which such party may then have under this Agreement.

19.   INDEPENDENT CONTRACTOR.

   A. In the performance of all services hereunder, Immtech shall be deemed to
      be and shall be an independent contractor and, as such, shall not be
      entitled to any benefits applicable to employees of UNC-CH.

   B. Neither party is authorized or empowered to act as agent for the other for
      any purpose and shall not on behalf of the other enter into any contract,
      warranty or representation as to any matter. Neither party shall be bound
      by the acts or conduct of the other.

20.   CHANGES TO THE PROTOCOL.

      If at a future date changes in the Research or Protocol appear desirable,
then such changes may be made through prior written agreement between UNC-CH and
Immtech. In the event that UNC-CH and Immtech disagree regarding any such
proposed change, then the Scientific Advisory Board appointed by UNC-CH to
oversee the Research shall resolve such disagreement. If in the course of
performing this Agreement, however, either of (a) generally accepted standards
of clinical research and medical practice relating to the safety of Research
Subjects, (b) a directive from the Institutional Review Board of UNC-CH with
authority over the Research, or (c) a decision of the Scientific Advisory Board
appointed by UNC-CH to oversee the Research, requires a deviation from the
Protocol, then such standards will be followed. In such case, the party aware of
the need for a deviation will immediately inform the other of the facts causing
such deviation as soon as the facts are known to the party. If the aggregate
amount of the costs of any and all required changes and/or deviations arising
pursuant to clauses (b) or (c) of this Article 20 during the term of this
Agreement, for which additional funding is not provided to Immtech by either the
Foundation, UNC-CH or any third party, exceed $300,000, then Immtech may
terminate this Agreement upon thirty (30) days written notice to UNC-CH.

21. CONFORMANCE WITH LAW AND ACCEPTED PRACTICE.

      Immtech shall perform the Research in conformance with generally accepted
standards of good clinical practice, with the Protocol, with instructions
provided by UNC-CH's Institutional Review Board and Scientific Advisory Boards,
and with all applicable local, state and federal or national laws and
regulations governing the performance of the Protocol and Research in the
countries involved in the clinical trials, including, but not limited to, the
Swiss Tropical Institute. Immtech shall retain all records resulting from the
Research for the time required by applicable regulations, and shall allow for
inspection by UNC-CH (during normal business hours and upon reasonable advance
notice, unless an emergency medical condition exists with respect to a Research
Subject) of all such records, including the Research Subjects' medical records.

                                      -13-
<PAGE>

22.   WAIVER.

      No waiver of any term, provision or condition of this Agreement, whether
by conduct or otherwise, in any one or more instances shall be deemed to be or
construed as a further or continuing waiver of any such term, provision or
condition, or of any other term, provision or condition of this Agreement.

    (Remainder of Page Intentionally Left Blank - Signature Page Follows)

                                      -14-
<PAGE>

      IN WITNESS WHEREOF, the parties hereto have executed this Agreement in
duplicate by proper persons thereunto duly authorized, as of the date first
above written.

THE UNIVERSITY OF NORTH             Immtech Phamaceuticals, Inc.
   CAROLINA AT CHAPEL HILL

By: /s/ Barbara M. Longmire         By: /s/ T. Stephen Thompson
--------------------------------    -------------------------------------
(signature)                         (signature)

Acting for                          T. Stephen Thompson
Tony G. Waldrop                     President
Vice Chancellor for Research
and Economic Development

March 28, 2006                      March 27, 2006
--------------------------------    -------------------------------------
Date                                Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}]]